---
title: "Pathophysiology Reference: Digestive System Conditions"
category: "Anatomy & Physiology"
tags:
  [
    "pathophysiology",
    "digestive system",
    "peptic ulcer",
    "H. pylori",
    "IBD",
    "IBS",
    "constipation",
    "diarrhea",
    "dysbiosis",
    "NAFLD",
    "gastritis",
    "celiac disease",
    "SIBO",
    "disease mechanisms",
    "reference",
  ]
date: "2025-11-12"
source: "Medical Herbalism (Hoffmann, 2003), Anatomy & Physiology (OpenStax), Fundamentals of Anatomy & Physiology, Clinical Integration"
---

# Pathophysiology Reference: Digestive System Conditions

**Context:** This comprehensive reference explains the disease mechanisms of common digestive conditions treated with herbal medicine. Understanding gastrointestinal pathophysiology is essential for selecting appropriate therapeutic strategies, as digestive health profoundly impacts overall wellbeing through nutrient absorption, immune function, and the gut-brain axis.

**Purpose:** To provide detailed pathophysiological understanding of:

- Upper GI disorders (peptic ulcer, gastritis, H. pylori)
- Functional GI disorders (IBS, functional dyspepsia)
- Inflammatory GI conditions (IBD, celiac disease)
- Lower GI disorders (constipation, diarrhea, SIBO)
- Hepatobiliary conditions (NAFLD, cholecystitis)
- Microbiome dysregulation

---

## Semantic Index

### Upper Gastrointestinal Conditions {#upper-gi}

- [Peptic Ulcer Disease](#peptic-ulcer) - H. pylori, NSAIDs, acid-pepsin imbalance
- [Gastritis](#gastritis) - Acute and chronic inflammation, autoimmune gastritis
- [H. pylori Infection](#h-pylori) - Pathogenesis, virulence factors, complications
- [Functional Dyspepsia](#functional-dyspepsia) - Visceral hypersensitivity, delayed gastric emptying

### Functional GI Disorders {#functional-gi}

- [Irritable Bowel Syndrome](#ibs) - Visceral hypersensitivity, gut-brain axis, SIBO
- [Small Intestinal Bacterial Overgrowth](#sibo) - Bacterial translocation, fermentation
- [Functional Constipation](#functional-constipation) - Slow transit, pelvic floor dysfunction

### Inflammatory Bowel Disease {#ibd}

- [Crohn's Disease](#crohns-disease) - Transmural inflammation, granulomas, fistulas
- [Ulcerative Colitis](#ulcerative-colitis) - Mucosal inflammation, continuous involvement
- [IBD Pathophysiology](#ibd-pathophysiology) - Immune dysregulation, genetics, microbiome

### Malabsorption and Autoimmune {#malabsorption}

- [Celiac Disease](#celiac-disease) - Gluten sensitivity, villous atrophy, autoantibodies
- [Non-Celiac Gluten Sensitivity](#ncgs) - Innate immune activation

### Intestinal Permeability and Dysbiosis {#permeability-dysbiosis}

- [Leaky Gut Syndrome](#leaky-gut) - Tight junction dysfunction, endotoxemia
- [Dysbiosis](#dysbiosis) - Microbiome imbalance, metabolic consequences
- [Candida Overgrowth](#candida) - Fungal dysbiosis, systemic effects

### Motility Disorders {#motility}

- [Constipation](#constipation) - Types, pathophysiology, complications
- [Diarrhea](#diarrhea) - Osmotic, secretory, inflammatory, infectious

### Hepatobiliary Conditions {#hepatobiliary}

- [Non-Alcoholic Fatty Liver Disease](#nafld) - Hepatic steatosis, NASH, cirrhosis
- [Cholecystitis and Cholelithiasis](#gallbladder) - Gallstones, inflammation

---

# Upper Gastrointestinal Conditions {#upper-gi}

## Peptic Ulcer Disease (PUD) {#peptic-ulcer}

### Definition

Peptic ulcer disease refers to erosions or ulcerations in the mucosa of the stomach (gastric ulcer) or duodenum (duodenal ulcer) that penetrate through the muscularis mucosae. These result from an imbalance between aggressive factors (acid, pepsin, H. pylori) and defensive factors (mucus, bicarbonate, prostaglandins, blood flow).

### Normal Gastric Defense Mechanisms

**Protective Factors:**

1. **Mucus Layer:**

   - Thick, adherent gel layer covering gastric epithelium
   - Composed of glycoproteins (mucins) secreted by surface mucous cells
   - Forms physical barrier preventing acid contact with epithelium
   - Traps bicarbonate, creating pH gradient (pH 1-2 in lumen → pH 7 at epithelial surface)

2. **Bicarbonate Secretion:**

   - Secreted by surface epithelial cells and duodenal Brunner's glands
   - Neutralizes acid within mucus layer
   - Maintains near-neutral pH at mucosal surface

3. **Prostaglandins (PGE₂, PGI₂):**

   - **Critical protective role:**
     - ↑ Mucus secretion
     - ↑ Bicarbonate secretion
     - ↑ Mucosal blood flow (delivers nutrients, removes acid)
     - ↓ Acid secretion
     - Promote epithelial cell proliferation (repair)
   - Produced constitutively by COX-1
   - **NSAIDs inhibit COX-1 → ↓ prostaglandins → loss of protection → ulcers**

4. **Epithelial Barrier:**

   - Tight junctions between epithelial cells prevent acid back-diffusion
   - Rapid cell turnover: Gastric epithelium replaced every 3-6 days

5. **Adequate Blood Flow:**
   - Delivers oxygen and nutrients
   - Removes acid that penetrates mucus layer
   - Delivers bicarbonate to neutralize acid

### Pathophysiology

#### Helicobacter pylori-Associated Ulcers (70-90% of duodenal ulcers, 60-70% of gastric ulcers)

**H. pylori Characteristics:**

- Gram-negative, spiral, microaerophilic bacterium
- Colonizes gastric mucosa (not duodenal mucosa)
- Affects ~50% of world population (varies by region)
- Transmission: Fecal-oral, oral-oral

**Virulence Factors:**

1. **Urease:**

   - H. pylori produces abundant urease enzyme
   - Converts urea → ammonia + CO₂
   - **Ammonia neutralizes gastric acid** → creates microenvironment allowing bacterial survival
   - Ammonia is directly toxic to epithelial cells

2. **Flagella:**

   - Allow motility through mucus layer
   - Bacterial chemotaxis toward epithelium

3. **Adhesins:**

   - Bacterial outer membrane proteins (BabA, SabA)
   - Bind to epithelial cell surface receptors
   - Prevent bacterial clearance by peristalsis

4. **Cytotoxin-Associated Gene A (CagA):**

   - Encoded by cag pathogenicity island
   - Injected into epithelial cells via type IV secretion system
   - **CagA-positive strains** associated with:
     - More severe gastritis
     - ↑ Risk of peptic ulcer
     - ↑ Risk of gastric cancer
   - CagA disrupts cell signaling, cytoskeletal structure, tight junctions

5. **Vacuolating Cytotoxin A (VacA):**
   - Induces vacuole formation in epithelial cells
   - Increases epithelial permeability
   - Inhibits T-cell activation (immune evasion)

**Mechanism of Ulcer Formation:**

**Duodenal Ulcers (H. pylori in antrum):**

1. H. pylori colonizes gastric antrum
2. Chronic antral gastritis develops
3. ↑ Gastrin secretion (G cells in inflamed antrum; reduced somatostatin inhibition)
4. ↑ Gastrin → ↑ parietal cell mass → ↑ acid secretion
5. ↑ Acid delivered to duodenum
6. **Gastric metaplasia** in duodenum (protective response to acid exposure)
7. H. pylori colonizes areas of gastric metaplasia in duodenum
8. Chronic duodenitis develops
9. Ulcer forms in inflamed, acid-exposed duodenal mucosa

**Gastric Ulcers (H. pylori in body/fundus):**

1. H. pylori colonizes gastric body
2. Chronic body gastritis (pangastritis)
3. ↓ Acid secretion (parietal cells damaged by inflammation)
4. BUT: Severe mucosal damage from:
   - Direct bacterial toxicity
   - Inflammatory cytokines (IL-1β, IL-8, TNF-α)
   - Neutrophil infiltration → oxidative damage
5. Loss of mucosal protection outweighs reduced acid
6. Ulcer forms in inflamed gastric mucosa

**Inflammatory Response:**

- H. pylori infection → acute and chronic inflammation
- **Neutrophil infiltration**: Release reactive oxygen species (ROS), proteases
- **Macrophage activation**: IL-1β, IL-8, TNF-α production
- **Lymphocyte infiltration**: Chronic inflammation; some progress to gastric lymphoma (MALT lymphoma)
- Inflammation damages epithelium, disrupts mucus/bicarbonate barrier

#### NSAID-Associated Ulcers (20-30% of ulcers)

**Mechanism:**

1. **COX-1 Inhibition (Primary Mechanism):**

   - NSAIDs non-selectively inhibit COX-1 and COX-2
   - **COX-1 inhibition → ↓ prostaglandin synthesis**
   - Loss of prostaglandin-mediated protection:
     - ↓ Mucus secretion
     - ↓ Bicarbonate secretion
     - ↓ Mucosal blood flow
     - ↓ Epithelial cell proliferation
   - Mucosa becomes vulnerable to acid-pepsin injury

2. **Direct Topical Injury:**

   - NSAIDs are weak acids
   - Accumulate in gastric epithelial cells
   - Direct cellular toxicity
   - **Uncoupling of oxidative phosphorylation** → ↓ ATP → cell death

3. **Reduced Healing:**
   - Prostaglandins promote repair
   - NSAID use → impaired healing of pre-existing erosions

**Risk Factors for NSAID Ulcers:**

- Age >60 years
- High-dose NSAIDs or multiple NSAIDs
- History of peptic ulcer or GI bleeding
- Concurrent use of anticoagulants, corticosteroids, or SSRIs
- H. pylori infection (synergistic effect)

**COX-2 Selective Inhibitors:**

- **Coxibs** (celecoxib, rofecoxib): Selectively inhibit COX-2
- COX-2 produces prostaglandins in inflammation but not GI protection (primarily COX-1)
- ↓ GI toxicity compared to non-selective NSAIDs
- **BUT**: ↑ Cardiovascular risk (COX-2 produces prostacyclin [PGI₂], a vasodilator and platelet inhibitor)

#### Other Causes of Peptic Ulcers (Rare)

- **Hypersecretory States:**
  - Zollinger-Ellison syndrome (gastrinoma → massive acid hypersecretion)
  - Systemic mastocytosis (histamine hypersecretion)
- **Stress Ulcers:**

  - **Cushing ulcers**: Associated with CNS trauma (↑ vagal stimulation → ↑ acid)
  - **Curling ulcers**: Associated with severe burns (↓ mucosal blood flow)
  - ICU patients on mechanical ventilation (stress, ischemia)

- **Crohn's Disease:**

  - Chronic inflammation can cause ulcers in stomach/duodenum

- **Malignancy:**
  - Gastric adenocarcinoma can present as ulcer (biopsy essential)

### Clinical Presentation

**Duodenal Ulcer:**

- **Epigastric pain**: Gnawing, burning, aching
- **Timing**: 2-5 hours after meals; often wakes patient at night (1-3 AM)
- **Relief**: Food or antacids temporarily relieve pain (food buffers acid)
- **Pattern**: Pain-food-relief cycle
- Often young to middle-aged adults

**Gastric Ulcer:**

- **Epigastric pain**: Similar character
- **Timing**: Shortly after eating (food stimulates acid secretion)
- **Worsened by**: Food (unlike duodenal ulcer)
- **Weight loss**: Patients may avoid eating (food causes pain)
- Older adults more common

**Other Symptoms:**

- Nausea and vomiting
- Bloating
- Belching
- Heartburn
- Early satiety

**Alarm Symptoms (require urgent evaluation):**

- Hematemesis (vomiting blood) or melena (black, tarry stools)
- Severe, persistent abdominal pain
- Unintended weight loss
- Anemia
- Dysphagia
- Persistent vomiting

### Complications

**1. Hemorrhage (15-20% of ulcers):**

- Most common complication
- Erosion into blood vessel
- Gastroduodenal artery (posterior duodenal ulcer) especially dangerous
- Presents as hematemesis, melena, or hematochezia (if brisk bleeding)
- Can cause hemodynamic instability, shock

**2. Perforation (2-10%):**

- Ulcer erodes through entire gastric/duodenal wall
- Gastric/duodenal contents leak into peritoneal cavity
- **Acute abdomen**: Sudden, severe pain; rigid, board-like abdomen
- **Peritonitis**: Life-threatening infection; requires emergency surgery
- **Pneumoperitoneum**: Free air under diaphragm on upright X-ray

**3. Penetration:**

- Ulcer erodes into adjacent organ (pancreas, liver)
- Pain becomes constant, radiates to back
- ↑ Amylase/lipase if pancreatic penetration

**4. Gastric Outlet Obstruction (<5%):**

- Chronic ulcers → scarring and fibrosis
- Narrowing of pyloric channel or duodenum
- Symptoms: Early satiety, postprandial fullness, nausea, vomiting (undigested food)
- **Succession splash**: Sloshing sound on abdominal exam
- Endoscopic dilation or surgery required

### Diagnosis

**Upper Endoscopy (EGD):**

- **Gold standard** for diagnosis
- Visualizes ulcer directly
- **Biopsy**:
  - Gastric ulcers: MUST biopsy to rule out malignancy
  - Duodenal ulcers: Benign (biopsy optional)
  - H. pylori testing (rapid urease test, histology, culture)

**H. pylori Testing:**

_Non-Invasive Tests:_

- **Urea Breath Test (UBT):**
  - Patient ingests ¹³C or ¹⁴C-labeled urea
  - If H. pylori present, urease cleaves urea → labeled CO₂ detected in breath
  - **Best non-invasive test**: High sensitivity and specificity (>95%)
  - Can assess eradication post-treatment
- **Stool Antigen Test:**
  - Detects H. pylori antigens in stool
  - Good sensitivity/specificity (~90-95%)
- **Serology (IgG antibodies):**
  - Indicates current or past infection
  - Cannot distinguish active from past infection
  - NOT useful for post-treatment testing (antibodies persist)

_Invasive Tests (during endoscopy):_

- **Rapid Urease Test (CLO test):**
  - Gastric biopsy placed in urea-containing medium with pH indicator
  - Color change indicates urease activity (H. pylori present)
  - Results in minutes to hours
- **Histology:**
  - Direct visualization of bacteria in biopsy specimen
  - Hematoxylin & eosin (H&E) or special stains (Giemsa, Warthin-Starry)
  - Also assesses gastritis severity
- **Culture:**
  - Allows antibiotic susceptibility testing
  - Technically difficult; not routine

**Important:** Discontinue PPIs 2 weeks before testing (false negatives)

**Upper GI Series (Barium Study):**

- Less sensitive than endoscopy
- Used if endoscopy contraindicated/unavailable
- "Ulcer crater" visible on X-ray

### Treatment

#### H. pylori Eradication

**Indications for Treatment:**

- Active peptic ulcer
- History of peptic ulcer
- MALT lymphoma
- After gastric cancer resection
- Uninvestigated dyspepsia with positive H. pylori test
- First-degree relatives of gastric cancer patients

**Standard Triple Therapy (10-14 days):**

- **PPI** (omeprazole, lansoprazole, esomeprazole) BID
- **Amoxicillin** 1g BID
- **Clarithromycin** 500mg BID

**Quadruple Therapy (if penicillin allergy or resistance concerns):**

- **PPI** BID
- **Bismuth subsalicylate** 524mg (2 tablets) QID
- **Metronidazole** 250mg QID or 500mg TID
- **Tetracycline** 500mg QID

**Eradication Rates:**

- Triple therapy: 70-85% (declining due to clarithromycin resistance)
- Quadruple therapy: 75-90%

**Post-Treatment Testing:**

- Urea breath test or stool antigen test ≥4 weeks after completion
- Do NOT use serology (antibodies persist)

#### Acid Suppression

**Proton Pump Inhibitors (PPIs):**

- **Mechanism**: Irreversibly inhibit H⁺/K⁺-ATPase (proton pump) in parietal cells
- **Examples**: Omeprazole, esomeprazole, lansoprazole, pantoprazole, rabeprazole
- **Dosing**: Standard dose once daily (or BID for H. pylori eradication)
- **Duration**:
  - Duodenal ulcer: 4-6 weeks
  - Gastric ulcer: 8-12 weeks (larger, slower healing)
  - NSAID ulcers: 8-12 weeks
- **Healing rates**: 90-95% at 4 weeks (duodenal), 8 weeks (gastric)
- **Long-term use concerns**:
  - ↓ B12 absorption (requires acidic pH)
  - ↓ Magnesium (chronic use)
  - ↑ Fracture risk (↓ calcium absorption)
  - ↑ C. difficile infection risk
  - ↑ Pneumonia risk (loss of gastric acid barrier)
  - Rebound acid hypersecretion upon discontinuation

**H2 Receptor Antagonists (H2RAs):**

- **Mechanism**: Block histamine-2 receptors on parietal cells
- **Examples**: Ranitidine (WITHDRAWN due to NDMA contamination), famotidine, cimetidine
- **Less effective than PPIs** for ulcer healing
- Used as alternative if PPI intolerant
- **Tachyphylaxis**: ↓ Effect with chronic use (days to weeks)

**Antacids:**

- Symptomatic relief only
- Do NOT promote healing
- Neutralize gastric acid

#### NSAID Ulcer Prevention

**For patients requiring NSAIDs:**

- **Co-prescribe PPI**: Most effective prevention strategy
- **Switch to COX-2 selective inhibitor** (celecoxib): ↓ GI risk (but ↑ CV risk)
- **Use lowest effective NSAID dose and shortest duration**
- **Consider alternatives**: Acetaminophen, tramadol

**Misoprostol (Cytotec):**

- Prostaglandin E₁ analog
- Replaces protective prostaglandins inhibited by NSAIDs
- Effective for NSAID ulcer prevention
- **Side effects**: Diarrhea, cramping (limits tolerability)
- **Contraindicated in pregnancy** (causes uterine contractions, abortion)

#### Lifestyle and Dietary Modifications

**Dietary:**

- **Avoid irritants**: Alcohol, coffee, spicy foods (if symptomatic)
- **Regular meals**: Avoid prolonged fasting (acid without food buffer)
- **No specific "ulcer diet" proven effective**

**Lifestyle:**

- **Smoking cessation**: Smoking impairs healing, increases recurrence
- **Stress management**: Stress does NOT cause ulcers, but may delay healing

### Herbal Therapeutic Targets in Peptic Ulcer Disease

| Mechanism                     | Herbal Actions                             | Representative Herbs                                 |
| ----------------------------- | ------------------------------------------ | ---------------------------------------------------- |
| **Mucosal Protection**        | Demulcent: Coat and protect gastric mucosa | Slippery Elm, Marshmallow, Licorice (DGL)            |
| **Mucosal Healing**           | Vulnerary: Promote epithelial repair       | Licorice (DGL), Calendula, Plantain                  |
| **Prostaglandin Enhancement** | ↑ Protective prostaglandins                | Licorice                                             |
| **Anti-H. pylori Activity**   | Antimicrobial against H. pylori            | Mastic Gum (Pistacia lentiscus), Licorice, Cranberry |
| **Acid Reduction**            | ↓ Acid secretion or neutralize acid        | Calcium carbonate (antacid - not herbal)             |
| **Anti-Inflammatory**         | ↓ Gastric inflammation                     | Calendula, Chamomile, Licorice                       |
| **Antioxidant**               | ↓ Oxidative stress from inflammation       | Turmeric, Green Tea                                  |
| **Urease Inhibition**         | Inhibit H. pylori urease enzyme            | Turmeric (curcumin)                                  |

**Specific Herbal Interventions:**

**1. Licorice (Glycyrrhiza glabra) - DGL (Deglycyrrhizinated Licorice):**

- **Remove glycyrrhizin** to avoid mineralocorticoid effects
- **Mechanisms**:
  - ↑ Mucus production
  - ↑ Prostaglandin synthesis (mucosal protection)
  - ↑ Mucosal blood flow
  - Anti-inflammatory
  - Promotes healing
  - Some anti-H. pylori activity
- **Dosing**: 380-1140mg chewable tablets, 20 minutes before meals, TID
- **Must be chewed** (saliva activates DGL)
- **Duration**: 8-12 weeks
- **Evidence**: Multiple studies show comparable efficacy to cimetidine for ulcer healing

**2. Mastic Gum (Pistacia lentiscus):**

- **Anti-H. pylori activity**:
  - Inhibits bacterial growth
  - Disrupts bacterial adherence
  - Clinical studies show H. pylori eradication in some patients
- **Dosing**: 1g daily in divided doses, for 2-4 weeks
- **Well-tolerated**

**3. Slippery Elm (Ulmus fulva/rubra):**

- **Demulcent**: Coats and protects mucosa
- **Dosing**: 1-2 tsp powder in water, sipped slowly, 3-4 times daily
- **Take between meals and before bed**

**4. Calendula (Calendula officinalis):**

- **Anti-inflammatory, vulnerary**
- Promotes mucosal healing
- **Dosing**: Tea or tincture, TID

**5. Plantain (Plantago major):**

- **Demulcent, vulnerary, astringent**
- Protects mucosa, promotes healing
- **Dosing**: Tea or tincture

**6. Chamomile (Matricaria chamomilla):**

- **Anti-inflammatory, antispasmodic**
- Soothes GI tract
- **Dosing**: Tea, 3-4 cups daily

**7. Cranberry (Vaccinium macrocarpon):**

- **Anti-adhesion properties**: Prevents bacterial adherence (studied for H. pylori)
- May complement conventional H. pylori eradication

**Clinical Protocol for Peptic Ulcer:**

**Acute Phase (during ulcer healing - 8-12 weeks):**

- **PPI** (if H. pylori negative and no NSAID use, PPIs optional but accelerate healing)
- **H. pylori eradication** if positive
- **DGL**: 380-1140mg chewable, 20 min before meals, TID
- **Slippery Elm**: 1-2 tsp in water, between meals and bedtime
- **Calendula or Chamomile tea**: 3-4 cups daily
- **Mastic gum**: 1g daily (if H. pylori positive, complement to antibiotics)
- **Avoid**: NSAIDs, alcohol, smoking

**Maintenance (after healing):**

- Continue DGL or intermittent demulcents if symptomatic
- Address lifestyle factors
- Stress management

**Clinical Note:** Peptic ulcer disease can lead to serious complications (hemorrhage, perforation). Alarm symptoms require immediate medical evaluation. Herbal therapy is effective for mild-moderate ulcers and as adjunctive therapy to conventional treatment. Always test for and eradicate H. pylori. NSAID-induced ulcers require discontinuation of NSAIDs if possible.

**Cross-Reference:**

- See `Licorice-Root-Comprehensive.md` for DGL mechanisms and dosing
- See `Digestive-System-Anatomy-Mechanisms.md` for gastric anatomy and acid physiology
- See `Calendula — Evidence-Based Clinical Monograph.md` for wound-healing properties

---

## Gastritis {#gastritis}

### Definition

Gastritis is inflammation of the gastric mucosa. It may be acute (sudden onset) or chronic (long-standing). Gastritis ranges from superficial mucosal inflammation to severe erosions and atrophy.

### Types of Gastritis

#### Acute Gastritis

**Causes:**

- **Alcohol**: Direct mucosal toxicity
- **NSAIDs**: ↓ Prostaglandins → loss of mucosal protection
- **Stress**: Critical illness, burns, CNS trauma (stress gastritis)
- **H. pylori**: Acute infection (rare presentation; most chronic)
- **Bile reflux**: Post-surgical (Billroth II)
- **Radiation**
- **Corrosive substances**: Acids, alkalis

**Pathophysiology:**

- Direct mucosal injury
- Inflammatory cell infiltration (neutrophils)
- Erosions (do not penetrate muscularis mucosae - distinguish from ulcers)
- Hemorrhage (can be severe in stress gastritis)

**Clinical Presentation:**

- Epigastric pain
- Nausea and vomiting
- Hematemesis or melena (if hemorrhagic)
- May be asymptomatic

**Treatment:**

- Remove offending agent
- Acid suppression (PPIs or H2RAs)
- Supportive care
- Usually resolves with removal of cause

#### Chronic Gastritis

**Types:**

**1. Chronic H. pylori Gastritis (Type B, Antral Gastritis):**

- **Most common type** (~80-90% of chronic gastritis)
- Primarily affects **gastric antrum** initially
- May progress to **pangastritis** (entire stomach)
- Chronic inflammation → **intestinal metaplasia** → ↑ gastric cancer risk

**Pathophysiology:**

- H. pylori colonization → chronic inflammatory response
- **Lymphocytic and plasma cell infiltration**
- Progressive mucosal damage
- **Intestinal metaplasia**: Gastric epithelium → intestinal-type epithelium with goblet cells
  - Precancerous condition
  - Correa's cascade: Normal mucosa → chronic gastritis → atrophic gastritis → intestinal metaplasia → dysplasia → adenocarcinoma
- **Gastric atrophy**: Loss of gastric glands (parietal cells, chief cells)
  - ↓ Acid secretion (hypochlorhydria or achlorhydria)
  - ↓ Intrinsic factor → B12 deficiency (if severe body involvement)

**Clinical Presentation:**

- Often asymptomatic
- Dyspepsia
- Early satiety
- ↑ Risk of gastric adenocarcinoma (especially intestinal-type)
- ↑ Risk of MALT lymphoma

**Diagnosis:**

- Endoscopy with biopsy
- H. pylori testing

**Treatment:**

- H. pylori eradication
- Surveillance endoscopy if intestinal metaplasia or dysplasia

**2. Autoimmune Gastritis (Type A, Fundic Gastritis):**

- **Autoimmune** destruction of parietal cells in gastric body/fundus
- **Antrum spared**
- Associated with **pernicious anemia**

**Pathophysiology:**

- **Autoantibodies**:
  - **Anti-parietal cell antibodies**: Target H⁺/K⁺-ATPase
  - **Anti-intrinsic factor antibodies**: Block B12-intrinsic factor binding or absorption
- Chronic inflammation → **gastric atrophy**
- Loss of parietal cells:
  - ↓ Hydrochloric acid (achlorhydria)
  - ↓ Intrinsic factor → **vitamin B12 malabsorption**
- Loss of chief cells → ↓ pepsinogen
- **Hypergastrinemia**: Low acid → loss of negative feedback → ↑ gastrin
  - ↑ Gastrin → **enterochromaffin-like (ECL) cell hyperplasia** → ↑ risk of **gastric carcinoid tumors** (neuroendocrine tumors)

**Clinical Presentation:**

- **Pernicious anemia**:
  - **Megaloblastic anemia**: Large, immature RBCs (B12 needed for DNA synthesis)
  - Symptoms: Fatigue, weakness, pallor, dyspnea
- **Neurological symptoms** (B12 deficiency):
  - Peripheral neuropathy: Paresthesias, numbness
  - **Subacute combined degeneration**: Demyelination of dorsal and lateral spinal cord columns
    - Ataxia, spasticity, loss of proprioception, loss of vibration sense
  - Cognitive impairment, dementia
  - Glossitis (sore, beefy-red tongue)
- Dyspepsia (less prominent)

**Diagnosis:**

- **Labs**:
  - ↓ Vitamin B12 (<200 pg/mL)
  - ↑ Methylmalonic acid (MMA) and homocysteine (more sensitive for B12 deficiency)
  - ↑ Gastrin (>1000 pg/mL)
  - Anemia: Macrocytic (↑ MCV), ↓ hemoglobin
  - ↓ Pepsinogen I (reflects parietal cell loss)
- **Serology**:
  - Anti-parietal cell antibodies (sensitive but not specific)
  - Anti-intrinsic factor antibodies (specific but less sensitive)
- **Endoscopy**: Atrophic changes in body/fundus; antrum normal
- **Schilling test** (historical; rarely used now): Assesses B12 absorption

**Treatment:**

- **Lifelong vitamin B12 supplementation**:
  - **Intramuscular** (IM) cyanocobalamin: 1000 mcg daily × 1 week, then weekly × 4 weeks, then monthly for life
  - **High-dose oral** B12 (1000-2000 mcg daily): Can be effective (small amount absorbed via passive diffusion)
  - **Sublingual or nasal** B12: Alternative routes
- **Surveillance endoscopy**: ↑ Risk of gastric carcinoid and adenocarcinoma
- **Iron supplementation**: If deficient (↓ acid impairs iron absorption)

**3. Chemical Gastritis (Reactive Gastropathy):**

- **Bile reflux**:
  - Post-surgical (Billroth II, gastrojejunostomy)
  - Cholecystectomy (↑ bile in stomach)
- **NSAIDs**: Chronic use
- **Alcohol**

**Pathophysiology:**

- Chemical injury to mucosa
- Foveolar hyperplasia (↑ mucus-secreting cells)
- Minimal inflammation (unlike infectious/autoimmune gastritis)
- Edema and congestion

**Clinical Presentation:**

- Epigastric pain
- Bilious vomiting
- Nausea

**Treatment:**

- Address underlying cause
- Sucralfate (mucosal protectant)
- Ursodeoxycholic acid (UDCA) - binds bile acids
- Prokinetics (metoclopramide, erythromycin) - improve gastric emptying

### Herbal Therapeutic Targets in Gastritis

| Mechanism                 | Herbal Actions                             | Representative Herbs                      |
| ------------------------- | ------------------------------------------ | ----------------------------------------- |
| **Mucosal Protection**    | Demulcent                                  | Slippery Elm, Marshmallow, Licorice (DGL) |
| **Mucosal Healing**       | Vulnerary                                  | Calendula, Plantain, Licorice             |
| **Anti-Inflammatory**     | ↓ Mucosal inflammation                     | Chamomile, Calendula, Turmeric            |
| **Antioxidant**           | ↓ Oxidative stress                         | Turmeric, Green Tea                       |
| **Prostaglandin Support** | ↑ Protective prostaglandins                | Licorice                                  |
| **Anti-H. pylori**        | Eradicate infection                        | Mastic Gum, Licorice                      |
| **B12 Supplementation**   | Address deficiency in autoimmune gastritis | Not herbal; B12 injections required       |

**Herbal Protocol for Gastritis:**

- **Acute gastritis**: Similar to peptic ulcer protocol (demulcents, vulneraries)
- **Chronic H. pylori gastritis**: H. pylori eradication + mucosal healing herbs
- **Autoimmune gastritis**: B12 replacement is PRIMARY treatment; herbs supportive only

**Clinical Note:** Chronic gastritis, especially with intestinal metaplasia, requires endoscopic surveillance for gastric cancer. Autoimmune gastritis requires lifelong B12 supplementation to prevent irreversible neurological damage.

---

## Helicobacter pylori Infection {#h-pylori}

_(See Peptic Ulcer Disease section above for detailed H. pylori pathophysiology)_

### Summary

**Epidemiology:**

- Infects ~50% of world population (higher in developing countries)
- Acquisition typically in childhood
- Transmission: Fecal-oral, oral-oral (possibly water, food)

**Clinical Outcomes:**

- **Most infected individuals (~85%)**: Asymptomatic chronic gastritis
- **~15-20%**: Develop peptic ulcer disease
- **~1-3%**: Develop gastric adenocarcinoma (decades after infection)
- **<1%**: Develop MALT lymphoma

**Diagnosis:**

- Non-invasive: Urea breath test (best), stool antigen, serology
- Invasive: Rapid urease test, histology, culture (during endoscopy)

**Treatment:**

- Triple or quadruple therapy (see Peptic Ulcer section)
- Confirm eradication with urea breath test or stool antigen ≥4 weeks post-treatment

**Prevention:**

- Improved sanitation and hygiene
- No vaccine available

**Cross-Reference:**

- See [Peptic Ulcer Disease](#peptic-ulcer) for detailed H. pylori pathophysiology

---

## Functional Dyspepsia {#functional-dyspepsia}

### Definition

Functional dyspepsia (FD) is chronic or recurrent epigastric pain or discomfort in the absence of organic disease (no ulcer, GERD, malignancy). It is a **functional GI disorder** (like IBS) characterized by symptoms without structural/biochemical abnormalities.

### Rome IV Diagnostic Criteria

Must include **≥1** of:

1. **Bothersome postprandial fullness** (early satiety)
2. **Bothersome epigastric pain**
3. **Bothersome epigastric burning**
4. **Bothersome early satiation**

**AND**:

- No evidence of structural disease (normal endoscopy)
- Symptoms for **≥6 months**
- Symptom frequency: **≥3 days/week in last 3 months**

**Subtypes:**

1. **Postprandial Distress Syndrome (PDS)**:

   - Meal-induced symptoms: Postprandial fullness, early satiation
   - May overlap with nausea, belching

2. **Epigastric Pain Syndrome (EPS)**:
   - Epigastric pain or burning
   - Not necessarily meal-related
   - May be improved or worsened by eating

### Pathophysiology

Multifactorial; incompletely understood

**1. Delayed Gastric Emptying (Gastroparesis):**

- Present in **30-40%** of FD patients
- Mechanisms:
  - Impaired fundic accommodation
  - Antral hypomotility
  - Pyloric dysfunction
- Leads to: Postprandial fullness, early satiety, nausea, bloating

**2. Impaired Gastric Accommodation:**

- **Normal**: Proximal stomach (fundus) relaxes to accommodate meal (receptive relaxation)
- **FD**: ↓ Fundic relaxation → ↑ intragastric pressure
- ↑ Pressure → premature distribution of food to antrum → early satiety
- Mediated by:
  - Vagal dysfunction
  - ↓ Nitric oxide (NO) - mediates smooth muscle relaxation
  - ↓ Serotonin signaling

**3. Visceral Hypersensitivity:**

- **Heightened perception of gastric distension**
- Normal gastric volumes perceived as painful/uncomfortable
- Mechanisms:
  - Sensitization of gastric mechanoreceptors
  - Central nervous system amplification (brain-gut axis)
  - ↓ Descending pain inhibition
- May explain epigastric pain/burning

**4. Duodenal Inflammation and Eosinophilia:**

- **Low-grade duodenal inflammation** found in many FD patients
- ↑ Eosinophils, mast cells
- May cause visceral hypersensitivity
- Mechanisms:
  - Immune activation
  - Release of inflammatory mediators (histamine, tryptase, prostaglandins)
  - Disrupted epithelial barrier
- Triggers unclear (food antigens?, infection?, stress?)

**5. H. pylori Infection:**

- Present in 40-60% of FD patients (geographic variation)
- Controversial role:
  - Some studies: H. pylori eradication improves symptoms in subset (10-15%)
  - May be more relevant in certain ethnic groups
  - Recommended to test and treat H. pylori in FD (small potential benefit)

**6. Altered Gut Microbiome:**

- Dysbiosis (microbial imbalance)
- ↑ Gram-negative bacteria in duodenum
- May contribute to inflammation and symptoms

**7. Psychological Factors:**

- **Strong association** with anxiety, depression, somatization
- **Gut-brain axis dysfunction**:
  - Stress affects GI motility, secretion, sensitivity
  - Altered brain processing of visceral pain
  - Hypothalamic-pituitary-adrenal (HPA) axis dysregulation
- **Bidirectional**: GI symptoms worsen mood; mood disorders worsen GI symptoms

**8. Genetic Factors:**

- Familial clustering
- Polymorphisms in serotonin transporter, G-protein β3 subunit, other genes

### Clinical Presentation

**Symptoms (as per Rome IV criteria):**

- Epigastric pain or burning
- Postprandial fullness
- Early satiety
- Bloating
- Nausea (common)
- Belching

**Symptoms typically:**

- Chronic (>6 months)
- Fluctuating severity
- No nocturnal symptoms (distinguish from organic disease)
- No weight loss (distinguish from malignancy)

**Alarm Features (suggest organic disease - require investigation):**

- Age >60 with new-onset symptoms
- Unintended weight loss
- GI bleeding (hematemesis, melena)
- Progressive dysphagia
- Persistent vomiting
- Family history of gastric cancer
- Palpable mass
- Anemia

### Diagnosis

**Clinical Diagnosis:**

- Rome IV criteria
- **Exclusion of organic disease**

**Upper Endoscopy (EGD):**

- **Indications**:
  - Alarm features
  - Age >60 (↑ gastric cancer risk)
  - Persistent symptoms
- **Findings**: Normal (by definition)
  - May have mild gastritis but no ulcer, malignancy

**H. pylori Testing:**

- Recommended for all FD patients
- Urea breath test or stool antigen

**Other Tests (to rule out alternative diagnoses):**

- **Gastric emptying study**: If gastroparesis suspected
  - Scintigraphy: Radiolabeled meal; measure emptying at 4 hours
  - Abnormal if >60% retained at 2 hours or >10% at 4 hours
- **Celiac serology**: Tissue transglutaminase (tTG) IgA
- **Metabolic panel**: TSH (hypothyroidism), calcium (hyperparathyroidism), glucose (diabetes)

### Treatment

**General Approach:**

- Multifactorial condition → multimodal therapy
- Address diet, stress, psychological factors
- Targeted therapy based on predominant symptoms

#### Dietary and Lifestyle Modifications

- **Small, frequent meals**: Reduce gastric distension
- **Avoid trigger foods**:
  - Fatty foods (delay gastric emptying)
  - Spicy foods
  - Carbonated beverages
  - Caffeine, alcohol
- **Food journal**: Identify personal triggers
- **Stress management**: Cognitive-behavioral therapy (CBT), mindfulness, relaxation techniques

#### Pharmacological Treatment

**1. Acid Suppression (if EPS - epigastric pain predominant):**

- **PPIs**: Trial for 4-8 weeks
  - Benefit in ~20-30% (overlaps with mild GERD)
  - Consider if burning/pain predominant
- **H2RAs**: Alternative (less effective)

**2. Prokinetics (if PDS - postprandial fullness predominant):**

- **Metoclopramide**:
  - Dopamine antagonist; ↑ gastric motility
  - Side effects: Extrapyramidal (tardive dyskinesia with long-term use), hyperprolactinemia
  - Use short-term only
- **Domperidone**:
  - Dopamine antagonist; does not cross blood-brain barrier
  - ↓ Neurological side effects compared to metoclopramide
  - Not available in USA (cardiac arrhythmia concerns)
- **Prucalopride**:
  - Serotonin 5-HT4 agonist
  - Approved for constipation; some benefit in FD

**3. H. pylori Eradication:**

- If positive, eradicate (see Peptic Ulcer section)
- 10-15% may see symptom improvement

**4. Neuromodulators (if refractory; psychological comorbidity):**

- **Tricyclic Antidepressants (TCAs)**:
  - Low-dose amitriptyline (10-50mg nightly)
  - Mechanisms: ↓ Visceral pain, central analgesic effects
  - Side effects: Anticholinergic (dry mouth, constipation)
- **SSRIs**: May help if anxiety/depression present

#### Psychological Therapies

- **Cognitive-Behavioral Therapy (CBT)**: Evidence-based
- **Hypnotherapy**: Gut-directed hypnotherapy
- **Mindfulness-based stress reduction**
- **Biofeedback**

### Herbal Therapeutic Targets in Functional Dyspepsia

| Mechanism             | Herbal Actions                        | Representative Herbs                           |
| --------------------- | ------------------------------------- | ---------------------------------------------- |
| **Prokinetic**        | ↑ Gastric motility, improve emptying  | Ginger, Artichoke, Bitter herbs (Gentian)      |
| **Carminative**       | Reduce bloating, gas, discomfort      | Peppermint, Fennel, Chamomile, Ginger          |
| **Antispasmodic**     | Reduce gastric spasm, pain            | Peppermint, Chamomile, Lemon Balm              |
| **Nervine**           | Address gut-brain axis, reduce stress | Chamomile, Lemon Balm, Passionflower, Lavender |
| **Anti-Inflammatory** | ↓ Duodenal inflammation               | Chamomile, Turmeric, Calendula                 |
| **Mucosal Healing**   | Support gastric/duodenal epithelium   | Licorice (DGL), Calendula, Slippery Elm        |
| **Adaptogenic**       | Modulate stress response (HPA axis)   | Ashwagandha, Holy Basil, Rhodiola              |

**Herbal Protocol for Functional Dyspepsia:**

**Postprandial Distress Syndrome (PDS - Fullness, Early Satiety):**

- **Bitters**: Gentian, Dandelion, Artichoke (15-30 min before meals) → stimulate motility
- **Ginger**: 1-2g daily → prokinetic, reduces nausea
- **Artichoke extract**: 320mg TID → improves gastric emptying, reduces fullness
- **Carminatives**: Fennel, Chamomile tea after meals
- **Digestive enzymes**: If food sits heavily

**Epigastric Pain Syndrome (EPS - Pain, Burning):**

- **Peppermint oil**: Enteric-coated, 0.2-0.4mL TID → antispasmodic
- **Chamomile**: 3-4 cups tea daily → anti-inflammatory, antispasmodic
- **Licorice (DGL)**: 380mg chewable before meals → mucosal protection
- **Lemon Balm**: 500mg TID → nervine, antispasmodic

**Both Subtypes + Stress Component:**

- **Nervines and Adaptogens**:
  - **Chamomile tea**: 3-4 cups daily
  - **Lemon Balm**: 300-500mg TID or tea
  - **Ashwagandha**: 300-600mg BID (if chronic stress, HPA dysfunction)
  - **Holy Basil**: 300-600mg BID or 2-3 cups tea
  - **Lavender oil**: 80-160mg capsules or aromatherapy

**Clinical Evidence:**

- **STW 5 (Iberogast)**: German herbal combination (9 herbs including peppermint, chamomile, caraway, licorice, etc.)
  - Multiple RCTs show efficacy for functional dyspepsia
  - Mechanisms: Prokinetic, antispasmodic, anti-inflammatory
  - Dosing: 20 drops TID before meals

**Clinical Note:** Functional dyspepsia is chronic and often refractory. Multimodal approach combining herbs, dietary modification, stress management, and psychological therapy is most effective. Address comorbid anxiety/depression. Reassure patient (no serious underlying disease).

**Cross-Reference:**

- See `Ginger_Monograph_Complete_Vector_Ready.md` for prokinetic mechanisms
- See `Chamomile_Monograph_VectorStore_Ready.md` for antispasmodic and nervine effects
- See `Digestive-System-Anatomy-Mechanisms.md` for gastric motility physiology

---

---

# Functional GI Disorders {#functional-gi}

## Irritable Bowel Syndrome (IBS) {#ibs}

### Definition

Irritable Bowel Syndrome is a chronic functional gastrointestinal disorder characterized by recurrent abdominal pain associated with altered bowel habits (diarrhea, constipation, or mixed) in the absence of organic disease. It affects 10-15% of the general population worldwide.

### Rome IV Diagnostic Criteria

**Must have:**
Recurrent abdominal pain, on average, **≥1 day/week** in the last 3 months

**Associated with ≥2 of the following:**

1. Related to defecation
2. Associated with change in frequency of stool
3. Associated with change in form (appearance) of stool

**AND:**

- Symptom onset ≥6 months prior to diagnosis
- Symptoms present during last 3 months

### IBS Subtypes (based on predominant bowel pattern)

**Determined by Bristol Stool Form Scale:**

| Subtype                              | Criteria                                   | Prevalence |
| ------------------------------------ | ------------------------------------------ | ---------- |
| **IBS-D** (Diarrhea-predominant)     | >25% Type 6-7 stools; <25% Type 1-2 stools | ~30%       |
| **IBS-C** (Constipation-predominant) | >25% Type 1-2 stools; <25% Type 6-7 stools | ~20%       |
| **IBS-M** (Mixed)                    | >25% Type 1-2 AND >25% Type 6-7 stools     | ~40%       |
| **IBS-U** (Unclassified)             | Does not meet criteria for above           | ~10%       |

**Bristol Stool Form Scale:**

- Type 1-2: Hard, lumpy stools (constipation)
- Type 3-4: Normal formed stools
- Type 5-7: Loose, watery stools (diarrhea)

### Pathophysiology

IBS is a **multifactorial disorder** involving complex interactions between:

- Visceral hypersensitivity
- Altered gut motility
- Gut-brain axis dysfunction
- Low-grade inflammation
- Altered gut microbiome
- Genetic factors
- Psychosocial factors

#### 1. Visceral Hypersensitivity

**Core Feature of IBS:**

- **Heightened perception of normal intestinal stimuli**
- Normal intestinal distension perceived as painful
- Reduced pain threshold in colon and rectum

**Mechanisms:**

_Peripheral Sensitization:_

- Increased density and excitability of nociceptors (pain receptors) in gut wall
- ↑ Expression of pain receptors (TRPV1, TRPA1)
- Release of sensitizing mediators:
  - Mast cell products (histamine, tryptase, prostaglandins)
  - Serotonin (5-HT) from enterochromaffin cells
  - Bradykinin
  - Nerve growth factor (NGF)

_Central Sensitization:_

- Amplification of pain signals in spinal cord and brain
- ↓ Descending pain inhibition from brainstem
- Altered brain processing of visceral pain
- Functional MRI studies show:
  - ↑ Activity in anterior cingulate cortex (emotional pain processing)
  - ↑ Activity in insula (interoception)
  - ↓ Activity in prefrontal cortex (pain modulation)

#### 2. Altered Gut Motility

**IBS-D:**

- ↑ Colonic motility
- Rapid transit time
- ↑ High-amplitude propagating contractions (HAPCs) - mass movements
- ↓ Segmental contractions - mixing

**IBS-C:**

- ↓ Colonic motility
- Slow transit time
- ↓ HAPCs
- ↑ Segmental (non-propulsive) contractions

**IBS-M:**

- Fluctuating motility patterns

**Mediators of Motility:**

- **Serotonin (5-HT)**: 95% of body's serotonin in gut
  - 5-HT3 receptors: Stimulate peristalsis, secretion
  - 5-HT4 receptors: Prokinetic
  - IBS-D: May have ↑ 5-HT or ↓ 5-HT reuptake
- **Bile acids**:
  - Stimulate colonic secretion and motility
  - IBS-D: May have bile acid malabsorption
- **Short-chain fatty acids (SCFAs)**:
  - Products of bacterial fermentation
  - Can stimulate or inhibit motility depending on concentration

#### 3. Gut-Brain Axis Dysfunction

**Bidirectional Communication:**

- **Brain to gut**: Stress affects GI function
  - Activation of hypothalamic-pituitary-adrenal (HPA) axis
  - ↑ Corticotropin-releasing factor (CRF) → ↑ colonic motility, ↑ permeability
  - Sympathetic and parasympathetic nervous system modulation
- **Gut to brain**: GI signals affect mood, cognition
  - Vagus nerve (80% afferent fibers)
  - Gut hormones (CCK, GLP-1, ghrelin)
  - Microbial metabolites (SCFAs, tryptophan metabolites)

**Psychological Comorbidity:**

- 50-60% of IBS patients have anxiety or depression
- **Childhood trauma/abuse**: Strong association with IBS development
- **Stress exacerbates symptoms** in majority of patients

**HPA Axis Dysregulation:**

- Altered cortisol responses to stress
- ↑ Pro-inflammatory cytokines with stress

#### 4. Post-Infectious IBS (PI-IBS)

**Epidemiology:**

- 10-15% of IBS cases follow acute gastroenteritis
- Risk factors for developing PI-IBS:
  - Severity and duration of acute illness
  - Female sex
  - Younger age
  - Psychological distress during infection
  - Use of antibiotics during infection

**Pathophysiology:**

- Persistent low-grade inflammation after infection resolves
- ↑ T-lymphocytes, mast cells, enterochromaffin cells in gut mucosa
- Altered gut microbiome (dysbiosis)
- Increased intestinal permeability ("leaky gut") - see Digestive-System-Anatomy-Mechanisms.md Gut Barrier Function section for detailed mechanisms
- Epithelial and neural remodeling

**Common Triggers:**

- Salmonella, Campylobacter, Shigella
- Viral gastroenteritis (norovirus, rotavirus)
- Protozoa (Giardia)

#### 5. Low-Grade Inflammation

**Mucosal Immune Activation:**

- ↑ Mast cells in colonic mucosa (release histamine, tryptase, prostaglandins)
- ↑ T-lymphocytes (especially in PI-IBS)
- ↑ Pro-inflammatory cytokines (IL-6, IL-1β, TNF-α) in subset of patients
- ↑ Intestinal permeability (see Digestive-System-Anatomy-Mechanisms.md Gut Barrier Function section for mechanisms)

**Mechanism:**

- Immune activation → mediator release → sensitization of nerves → visceral hypersensitivity and altered motility

#### 6. Gut Microbiome Alterations (Dysbiosis)

**Microbiome Differences in IBS:**

- ↓ Overall diversity
- ↓ Bifidobacterium, Lactobacillus (beneficial bacteria)
- ↑ Firmicutes:Bacteroidetes ratio (variable)
- Individual variability (no single "IBS microbiome")

**Consequences:**

- Altered fermentation → ↑ gas production → bloating, distension
- ↑ Short-chain fatty acids → altered motility and secretion
- Altered metabolism of bile acids → diarrhea (if ↑ primary bile acids stimulate colon)
- Disrupted intestinal barrier → ↑ permeability
- Altered neurotransmitter production (serotonin, GABA)
- Immune activation

#### 7. Small Intestinal Bacterial Overgrowth (SIBO)

**Prevalence in IBS:**

- Estimated 30-80% of IBS patients have SIBO (varies by testing method)
- More common in IBS-D

**Pathophysiology:**

- Excessive bacteria in small intestine (normally relatively sterile)
- Bacterial fermentation of carbohydrates → gas (H₂, CH₄, H₂S)
- Symptoms: Bloating, distension, diarrhea, abdominal pain
- See [SIBO section](#sibo) for details

#### 8. Food Sensitivities and Intolerances

**FODMAPs:**

- **Fermentable Oligosaccharides, Disaccharides, Monosaccharides, And Polyols**
- Poorly absorbed carbohydrates
- Fermented by gut bacteria → gas production
- Osmotic effect → draw water into intestines
- 50-75% of IBS patients improve with low-FODMAP diet

**Other Food Triggers:**

- **Gluten**: Non-celiac gluten sensitivity may overlap with IBS
- **Dairy**: Lactose intolerance (if lactase deficient)
- **Fatty foods**: Delay gastric emptying, stimulate visceral afferents
- Individual triggers vary

#### 9. Genetic Factors

- Familial clustering (33% have first-degree relative with IBS)
- Polymorphisms identified:
  - Serotonin transporter gene (5-HTTLPR)
  - Serotonin receptors (HTR3)
  - Bile acid synthesis genes
  - Immune-related genes (IL-10, TNF-α)

### Clinical Presentation

**Core Symptoms:**

- **Abdominal pain/cramping**:
  - Location: Often lower abdomen (but can be anywhere)
  - Character: Cramping, aching, sharp
  - Relieved by defecation
  - **Key diagnostic feature**: Pain MUST be present for IBS diagnosis
- **Altered bowel habits**:
  - Diarrhea (IBS-D): Loose/watery stools, urgency, frequent
  - Constipation (IBS-C): Hard stools, straining, incomplete evacuation
  - Mixed (IBS-M): Alternating diarrhea and constipation
- **Bloating and distension**: Very common; visible abdominal swelling
- **Urgency**: Need to defecate immediately (IBS-D)
- **Incomplete evacuation**: Feeling that bowel not completely emptied (IBS-C)

**Associated Symptoms:**

- Mucus in stool (common, benign)
- Gas and flatulence
- Nausea
- Worsened by stress or certain foods
- **Symptoms typically better overnight** (distinguish from organic disease)

**Extraintestinal Symptoms (common comorbidities):**

- Fibromyalgia (20-50%)
- Chronic fatigue syndrome
- Anxiety and depression (50-60%)
- Headaches/migraines
- Urinary symptoms (frequency, urgency)
- Dysmenorrhea (painful periods)
- Sexual dysfunction

**Red Flags (suggest organic disease - NOT IBS):**

- Age >50 with new-onset symptoms
- Unintentional weight loss
- Rectal bleeding (not from hemorrhoids)
- Anemia
- Fever
- Nocturnal symptoms that wake patient from sleep
- Family history of IBD, celiac disease, or colon cancer
- Severe, progressive symptoms
- Abnormal physical exam findings

### Diagnosis

**Clinical Diagnosis:**

- Based on **Rome IV criteria**
- **Symptom-based diagnosis** (no definitive test)

**Diagnostic Testing (to rule out organic disease):**

**First-Line Tests:**

- **Complete blood count (CBC)**: Rule out anemia
- **C-reactive protein (CRP) or fecal calprotectin**: Rule out IBD (normal in IBS)
- **Celiac serology**: Tissue transglutaminase (tTG) IgA + total IgA
  - 4-5% of IBS patients have celiac disease
- **Thyroid-stimulating hormone (TSH)**: Rule out hyperthyroidism (diarrhea) or hypothyroidism (constipation)

**If Alarm Features or Red Flags:**

- **Colonoscopy**: Rule out IBD, cancer, microscopic colitis
- **Stool studies**: Ova and parasites (O&P), bacterial culture, Giardia antigen, C. difficile toxin

**Additional Tests (Selected Patients):**

- **Hydrogen/methane breath test**: Diagnose SIBO or lactose intolerance
- **Fecal elastase**: Pancreatic insufficiency (if steatorrhea)
- **24-hour stool collection**: Quantify diarrhea
- **Bile acid malabsorption tests**: SeHCAT scan (not available US); empiric trial of bile acid sequestrant

**Note:** Extensive testing generally NOT needed if typical IBS presentation without red flags

### Treatment

**Multifaceted Approach:**

- Diet and lifestyle modifications
- Pharmacotherapy (symptom-targeted)
- Psychological therapies
- Herbal and complementary therapies

#### Dietary Management

**Low-FODMAP Diet:**

- **Elimination phase** (4-6 weeks): Restrict high-FODMAP foods
- **Reintroduction phase**: Systematically reintroduce FODMAPs to identify personal triggers
- **Personalization phase**: Ongoing diet tailored to individual tolerances
- **Efficacy**: 50-75% symptom improvement

**High-FODMAP Foods to Restrict:**

- **Oligosaccharides**: Wheat, rye, onions, garlic, legumes
- **Disaccharides**: Lactose (milk, yogurt, soft cheese)
- **Monosaccharides**: Fructose (honey, apples, high fructose corn syrup)
- **Polyols**: Sorbitol, mannitol (stone fruits, sugar-free gum)

**Other Dietary Strategies:**

- **Gluten-free diet**: May help subset (non-celiac gluten sensitivity)
- **Lactose-free**: If lactose intolerant
- **Soluble fiber supplementation**: Psyllium (↓ symptoms; especially IBS-C)
- **Avoid trigger foods**: Fatty foods, spicy foods, caffeine, alcohol (individualized)
- **Regular meal patterns**: Avoid skipping meals or large meals

**Probiotics:**

- **Bifidobacterium** species (B. infantis 35624, B. longum): Evidence for symptom reduction
- **Lactobacillus** species (variable efficacy)
- **Multi-strain probiotics**: May be more effective
- **Mechanism**: Restore microbiome balance, ↓ inflammation, improve barrier function

#### Pharmacotherapy

**IBS-D (Diarrhea-Predominant):**

- **Loperamide** (Imodium): Antidiarrheal; slows motility
- **Rifaximin**: Non-absorbable antibiotic; treats SIBO; improves bloating and diarrhea
- **Alosetron** (5-HT3 antagonist): ↓ Motility and pain; restricted use (risk of ischemic colitis)
- **Eluxadoline**: Mixed mu-opioid agonist / delta-opioid antagonist; ↓ diarrhea and pain
- **Bile acid sequestrants** (cholestyramine, colesevelam): If bile acid malabsorption

**IBS-C (Constipation-Predominant):**

- **Fiber supplementation**: Psyllium (soluble fiber)
- **Osmotic laxatives**: Polyethylene glycol (PEG), magnesium
- **Lubiprostone**: Chloride channel activator; ↑ intestinal fluid secretion
- **Linaclotide** or **Plecanatide**: Guanylate cyclase-C agonists; ↑ secretion, ↑ motility, ↓ pain
- **Prucalopride**: 5-HT4 agonist; prokinetic

**Abdominal Pain/Spasm:**

- **Antispasmodics**:
  - Hyoscyamine, dicyclomine (anticholinergics)
  - Peppermint oil (natural antispasmodic)
- **Neuromodulators** (if refractory):
  - **TCAs** (amitriptyline, nortriptyline): Low-dose; ↓ visceral pain
  - **SSRIs** (citalopram, paroxetine): May help with pain and mood

**Bloating:**

- Rifaximin (if SIBO)
- Low-FODMAP diet
- Simethicone (limited efficacy)

#### Psychological Therapies

**Evidence-Based:**

- **Cognitive-Behavioral Therapy (CBT)**: ↓ Symptoms, improve coping
- **Gut-Directed Hypnotherapy**: Effective for refractory IBS
- **Mindfulness-Based Stress Reduction (MBSR)**
- **Relaxation techniques**: Progressive muscle relaxation, deep breathing

**Rationale:**

- Address gut-brain axis dysfunction
- Reduce stress, anxiety, depression
- Improve coping and quality of life

### Herbal Therapeutic Targets in IBS

| Mechanism                   | Herbal Actions                      | Representative Herbs                                         |
| --------------------------- | ----------------------------------- | ------------------------------------------------------------ |
| **Antispasmodic**           | ↓ Intestinal cramping and spasm     | Peppermint oil, Chamomile, Lemon Balm, Fennel                |
| **Carminative**             | ↓ Bloating, gas, distension         | Peppermint, Fennel, Ginger, Chamomile, Caraway               |
| **Nervine**                 | Address gut-brain axis, ↓ stress    | Chamomile, Lemon Balm, Passionflower, Lavender, Skullcap     |
| **Astringent** (IBS-D)      | ↓ Diarrhea, tone intestinal mucosa  | Blackberry leaf, Raspberry leaf, Potentilla erecta, Agrimony |
| **Gentle Laxative** (IBS-C) | Improve bowel movements             | Psyllium, Flaxseed, Triphala                                 |
| **Anti-Inflammatory**       | ↓ Low-grade inflammation            | Turmeric, Chamomile, Boswellia, Calendula                    |
| **Antimicrobial** (if SIBO) | Reduce bacterial overgrowth         | Berberine herbs, Oregano oil, Neem                           |
| **Probiotic**               | Restore microbiome                  | Bifidobacterium, Lactobacillus                               |
| **Adaptogenic**             | Modulate stress response (HPA axis) | Ashwagandha, Holy Basil, Rhodiola                            |

### Comprehensive Herbal Protocol for IBS

#### IBS-D (Diarrhea-Predominant)

**Core Herbs:**

1. **Peppermint Oil (Mentha × piperita)**:

   - **Enteric-coated capsules**: 0.2-0.4 mL (187-374 mg peppermint oil) TID, 30-60 min before meals
   - **Mechanism**: Calcium channel blocker → antispasmodic; ↓ pain, ↓ cramping
   - **Evidence**: Multiple RCTs show efficacy for IBS pain and global symptoms
   - **Caution**: Avoid in GERD (relaxes LES); heartburn if not enteric-coated

2. **Astringent Herbs** (↓ diarrhea):

   - **Blackberry leaf (Rubus fruticosus)**: 2-4 mL tincture TID or tea
   - **Raspberry leaf (Rubus idaeus)**: Tea (1-2 cups daily) or tincture
   - **Potentilla erecta (Tormentil)**: 2-3 mL tincture TID
   - **Agrimony (Agrimonia eupatoria)**: Tea or tincture
   - **Mechanism**: Tannins → astringent, reduce intestinal secretions, tone mucosa

3. **Chamomile (Matricaria chamomilla)**:

   - **Tea**: 3-4 cups daily (especially after meals, before bed)
   - **Tincture**: 2-4 mL TID
   - **Mechanism**: Antispasmodic, anti-inflammatory, carminative, nervine
   - **Addresses multiple IBS mechanisms**

4. **Nervines** (address gut-brain axis):

   - **Lemon Balm (Melissa officinalis)**: 300-500 mg TID or tea
   - **Passionflower (Passiflora incarnata)**: 2-4 mL tincture TID
   - **Skullcap (Scutellaria lateriflora)**: 2-4 mL tincture TID
   - **Lavender (Lavandula angustifolia)**: 80-160 mg capsules or aromatherapy

5. **Probiotics**:
   - **Bifidobacterium infantis 35624**: 1 × 10⁸ CFU daily
   - **Multi-strain probiotic**: At least 10 billion CFU daily
   - **Duration**: Minimum 4-8 weeks

**Supportive:**

- **Psyllium husk**: 3-5g with water TID (forms bulk, absorbs excess fluid)
- **Slippery Elm**: 1-2 tsp powder in water, 2-3 times daily (demulcent)

#### IBS-C (Constipation-Predominant)

**Core Herbs:**

1. **Bulk-Forming Laxatives**:

   - **Psyllium (Plantago psyllium)**: 5-10g in 8-10 oz water, 1-3 times daily
   - **Flaxseed (Linum usitatissimum)**: 1-3 Tbsp ground seeds with water daily
   - **Chia seeds**: 1-2 Tbsp with water
   - **MUST take with adequate water** (risk of obstruction otherwise)

2. **Bitters** (stimulate peristalsis):

   - **Gentian (Gentiana lutea)**: 10-30 drops tincture in water, 15-30 min before meals
   - **Dandelion root (Taraxacum officinale)**: 2-5 mL tincture TID or tea
   - **Artichoke (Cynara scolymus)**: 320mg extract TID

3. **Gentle Stimulant Laxatives** (short-term rescue if needed):

   - **Triphala**: Ayurvedic formula (3 fruits); 500-1000 mg before bed
   - **Senna (Senna alexandrina)**: 15-30 mg sennosides before bed
   - **Cascara (Rhamnus purshiana)**: 20-30 mg cascarosides before bed
   - **USE SHORT-TERM ONLY** (<2 weeks); risk of dependence

4. **Magnesium**:

   - **Magnesium citrate** or **magnesium oxide**: 300-600 mg daily
   - **Osmotic laxative effect**: Draws water into intestines
   - **Additional benefit**: Muscle relaxation

5. **Peppermint Oil**: Same as IBS-D (antispasmodic for cramping)

6. **Nervines**: Same as IBS-D

7. **Probiotics**: Same as IBS-D

#### IBS-M (Mixed) or All Subtypes

**Comprehensive Protocol:**

1. **Peppermint oil**: Enteric-coated, TID
2. **Chamomile tea**: 3-4 cups daily
3. **Adaptogenic nervines**:
   - **Ashwagandha (Withania somnifera)**: 300-600 mg BID
   - **Holy Basil (Ocimum sanctum)**: 300-600 mg BID or 2-3 cups tea
   - **Mechanism**: Modulate HPA axis, improve stress resilience, ↓ anxiety
4. **Turmeric (Curcuma longa)**: 500-1000 mg BID (anti-inflammatory)
5. **Probiotics**: Multi-strain, 10-20 billion CFU daily
6. **Digestive enzymes**: If bloating prominent (taken with meals)

#### If SIBO Suspected (Hydrogen Breath Test Positive or High Clinical Suspicion)

**Herbal Antimicrobial Protocol** (2-4 weeks):

1. **Berberine** (from Berberis, Coptis, Hydrastis): 500 mg TID
2. **Oregano oil (Origanum vulgare)**: 200 mg enteric-coated, TID
3. **Neem (Azadirachta indica)**: 300-500 mg TID
4. **Allicin (from garlic)**: 300-500 mg TID

**OR**:

- **Candibactin-AR + Candibactin-BR** (commercial herbal SIBO protocol): As directed
- **FCdysbiocide + FC Cidal** (Biotics Research): As directed

**Evidence**: Herbal antimicrobials comparable to rifaximin for SIBO eradication

**After Antimicrobial Phase:**

- **Probiotics**: Restore beneficial bacteria
- **Prokinetics**: Prevent recurrence (Ginger 1-2g daily; MotilPro supplement)

### Clinical Evidence for Herbal Therapies in IBS

**Peppermint Oil:**

- **Meta-analysis** (Ford et al., 2014): Peppermint oil significantly better than placebo for global IBS symptoms (RR 2.2)
- **Dose**: Enteric-coated 0.2-0.4 mL TID
- **NNT (Number Needed to Treat)**: 2-3 (very effective)

**STW 5 (Iberogast):**

- German herbal combination (9 herbs)
- Multiple RCTs show efficacy for IBS symptoms
- Not widely available in USA

**Probiotics:**

- **Bifidobacterium infantis 35624**: Reduced pain, bloating, bowel habit abnormalities (Whorwell et al., 2006)
- **Multi-strain probiotics**: Variable efficacy; may be more effective than single strains

**Turmeric:**

- Pilot study showed improvement in IBS symptoms and quality of life (Bundy et al., 2004)

**Herbal Antimicrobials for SIBO:**

- **Study** (Chedid et al., 2014): Herbal therapy comparable to rifaximin for SIBO eradication (46% vs 34%, not statistically different)

### Lifestyle and Stress Management

**Essential Components:**

- **Regular exercise**: Improves motility, ↓ stress, ↑ quality of life
- **Adequate sleep**: 7-9 hours nightly
- **Stress reduction**:
  - Yoga, tai chi
  - Meditation, mindfulness
  - Deep breathing exercises
  - Regular relaxation practice
- **Avoid smoking**: Exacerbates symptoms
- **Limit alcohol and caffeine**: GI irritants
- **Psychotherapy**: CBT, hypnotherapy (if accessible)

### Prognosis

**Chronic Condition:**

- IBS is chronic; symptoms wax and wane
- **No increased risk** of IBD, colon cancer, or mortality
- **Quality of life** significantly impacted in many patients
- **Goal**: Symptom management, improved coping, maintain function

**Response to Treatment:**

- 50-75% improve with comprehensive management
- Requires individualized, multimodal approach
- Trial and error to find effective regimen
- Long-term management often needed

**Clinical Note:** IBS is a diagnosis of exclusion requiring Rome IV criteria and absence of alarm features. It's a real, physiological condition (not "all in the head"), though psychological factors contribute. Multimodal therapy combining diet (low-FODMAP), herbs (peppermint oil, chamomile, astringents/laxatives as needed, nervines), probiotics, stress management, and psychological support is most effective. Always rule out celiac disease, IBD, and SIBO. Reassure patient that IBS does not lead to serious disease.

**Cross-Reference:**

- See `Peppermint_Monograph_Vector_Store_Ready.md` for detailed peppermint oil use in IBS
- See `Chamomile_Monograph_VectorStore_Ready.md` for antispasmodic and nervine effects
- See `Digestive-System-Anatomy-Mechanisms.md` for gut-brain axis, motility, and IBS pathophysiology
- See `Nervous-System-Anatomy-Mechanisms.md` for HPA axis and stress physiology
- See [SIBO section](#sibo) for bacterial overgrowth details

---

## Small Intestinal Bacterial Overgrowth (SIBO) {#sibo}

### Definition

SIBO is defined as the presence of **≥10³ colony-forming units (CFU) per milliliter** of bacteria in the proximal small intestine, or an **increase in colonic-type bacteria** in the small intestine. Normally, the small intestine is relatively sterile compared to the colon (10³-10⁴ CFU/mL vs 10¹¹-10¹² CFU/mL).

### Epidemiology

**Prevalence:**

- General population: ~6-15%
- IBS patients: 30-80% (varies by testing method and diagnostic criteria)
- Elderly (>65): 15-30%
- Post-surgical patients (gastric bypass, small bowel resection): 30-50%

### Pathophysiology

#### Normal Small Intestinal Bacterial Homeostasis

**Protective Mechanisms:**

1. **Gastric acid**: Kills most ingested bacteria
2. **Bile acids**: Antimicrobial properties
3. **Pancreatic enzymes**: Some antimicrobial activity
4. **Intestinal motility**:
   - **Migrating Motor Complex (MMC)**: "Housekeeping" contractions during fasting
   - Phase III contractions sweep bacteria from small intestine into colon
   - Occurs every 90-120 minutes during fasting
5. **Ileocecal valve**: Prevents reflux of colonic bacteria into ileum
6. **Intestinal immune system**: Secretory IgA, antimicrobial peptides (defensins)
7. **Mucus layer**: Physical barrier

#### SIBO Development: Loss of Protective Mechanisms

**Risk Factors:**

**1. Impaired Gastric Acid Secretion:**

- **Proton pump inhibitors (PPIs)**: Most common cause
- **H2 receptor antagonists**
- **Atrophic gastritis** (H. pylori, autoimmune)
- **Pernicious anemia**

**2. Impaired Intestinal Motility:**

- **Diabetes mellitus**: Autonomic neuropathy → gastroparesis, intestinal dysmotility
- **Scleroderma**: Smooth muscle atrophy → dysmotility
- **Hypothyroidism**: Slowed motility
- **Opioid use**: Constipating, slows motility
- **Intestinal pseudo-obstruction**: Chronic motility disorder

**3. Anatomical Abnormalities:**

- **Intestinal strictures**: Crohn's disease, radiation enteritis, adhesions
- **Diverticula**: Small bowel diverticula trap bacteria
- **Fistulas**: Abnormal connections allow bacterial translocation
- **Ileocecal valve dysfunction**: Allows reflux of colonic bacteria
- **Blind loops**: Post-surgical (Billroth II, Roux-en-Y)

**4. Impaired Immune Function:**

- **Immunodeficiency**: IgA deficiency, HIV/AIDS
- **Chronic pancreatitis**: ↓ Pancreatic enzymes and bicarbonate
- **Cirrhosis**: Portal hypertension → bacterial translocation

**5. Other Conditions:**

- **Celiac disease**: Mucosal damage, motility changes
- **Crohn's disease**: Strictures, fistulas, dysmotility
- **Chronic kidney disease**
- **Advanced age**: ↓ Acid secretion, ↓ motility, medications

#### Consequences of SIBO

**1. Malabsorption:**

- **Fat malabsorption**:
  - Bacteria deconjugate bile acids → impaired micelle formation → fat malabsorption
  - Steatorrhea (fatty stools)
  - Fat-soluble vitamin deficiencies (A, D, E, K)
- **Carbohydrate malabsorption**:
  - Bacterial fermentation of carbohydrates → gas (H₂, CH₄, CO₂)
  - Osmotic diarrhea
- **Protein malabsorption** (less common)

**2. Vitamin Deficiencies:**

- **Vitamin B12**:
  - Bacteria consume B12 → deficiency
  - Can lead to megaloblastic anemia, neuropathy
- **Fat-soluble vitamins** (A, D, E, K): Due to fat malabsorption
- **Folate**: May be ↑ (bacterial synthesis) but bioavailability questionable

**3. Mucosal Damage:**

- Bacterial toxins and metabolites damage intestinal epithelium
- ↑ Intestinal permeability (see Digestive-System-Anatomy-Mechanisms.md Gut Barrier Function section for mechanisms) ("leaky gut")
- Villous atrophy (if severe, chronic)
- Inflammation

**4. Gas Production and Bloating:**

- **Hydrogen gas (H₂)**: Produced by most bacteria
- **Methane gas (CH₄)**: Produced by methanogens (Methanobrevibacter smithii)
  - **Methane associated with constipation** (slows transit)
- **Hydrogen sulfide (H₂S)**: Produced by sulfate-reducing bacteria
  - Controversial role; may be associated with diarrhea
- Result: Bloating, distension, abdominal discomfort

**5. Systemic Effects:**

- D-Lactic acidosis (rare): From bacterial fermentation; causes confusion, ataxia
- Bacterial translocation: Bacteria cross into bloodstream → risk of sepsis (immunocompromised)

### Clinical Presentation

**Symptoms:**

- **Bloating and abdominal distension**: Most common (95%)
- **Diarrhea**: Osmotic, steatorrhea
  - May alternate with constipation
  - Methane-predominant SIBO → constipation
- **Abdominal pain/cramping**: Often postprandial (after eating)
- **Gas and flatulence**: Excessive, foul-smelling
- **Weight loss**: Malabsorption
- **Nutritional deficiencies**:
  - Anemia (B12, iron)
  - Neuropathy (B12)
  - Night blindness (vitamin A)
  - Osteoporosis (vitamin D, calcium malabsorption)

**Physical Exam:**

- Often unremarkable
- Abdominal distension
- Signs of malnutrition (if chronic, severe)

**Conditions Associated with SIBO:**

- **IBS** (30-80% overlap)
- **Celiac disease**
- **Crohn's disease**
- **Scleroderma**
- **Diabetes mellitus**
- **Fibromyalgia** (possible gut-brain axis connection)
- **Rosacea** (controversial association)
- **Restless leg syndrome** (due to iron deficiency?)

### Diagnosis

**Gold Standard:**

- **Jejunal aspirate and culture**: ≥10³ CFU/mL diagnostic
- **Rarely performed**: Invasive, expensive, requires endoscopy, contamination risk

**Practical Diagnostic Tests:**

**1. Hydrogen/Methane Breath Testing:**

- **Most commonly used test**
- **Lactulose Breath Test**:
  - Patient drinks lactulose (non-absorbable sugar)
  - Exhaled hydrogen (H₂) and methane (CH₄) measured every 15-20 minutes for 2-3 hours
  - **Positive if**:
    - ↑ H₂ ≥20 ppm above baseline within 90 minutes
    - ↑ CH₄ ≥10 ppm at any point
    - Early peak (<90 min) suggests small intestine fermentation
  - **Sensitivity**: ~60-70%
  - **Specificity**: ~70-80%
- **Glucose Breath Test**:
  - Glucose absorbed in proximal small intestine (normally)
  - If SIBO present, bacteria ferment glucose → ↑ H₂/CH₄
  - **Positive if**: ↑ H₂ ≥20 ppm or ↑ CH₄ ≥10 ppm within 90-120 minutes
  - More specific for proximal SIBO but may miss distal SIBO

**Interpretation:**

- **Hydrogen-positive**: Hydrogen-producing bacteria
- **Methane-positive**: Methanogenic archaea (Methanobrevibacter smithii)
  - Associated with constipation-predominant symptoms
- **Hydrogen sulfide (H₂S)**: Not routinely measured (requires special testing)

**Preparation:**

- **4-week washout**: Antibiotics, probiotics
- **24-hour diet**: Low fiber, no fermentable foods
- **12-hour fast** before test
- **No smoking, exercise** morning of test

**2. Small Bowel Aspirate Culture:**

- Endoscopy with aspiration of small intestinal fluid
- Culture for aerobic and anaerobic bacteria
- ≥10³ CFU/mL diagnostic
- **Limitations**: Invasive, expensive, risk of contamination

**3. Empiric Trial of Antibiotics:**

- If high clinical suspicion, trial of rifaximin
- Symptom improvement suggests SIBO

**Laboratory Tests (assess complications):**

- **CBC**: Anemia (macrocytic if B12 deficient; microcytic if iron deficient)
- **Vitamin B12 level**: May be low
- **Folate**: May be elevated (bacterial synthesis)
- **Fat-soluble vitamins** (A, D, E, K)
- **Fecal fat** (72-hour collection): Quantify steatorrhea
- **D-xylose test**: Malabsorption screen (rarely used)

### Treatment

**Goals:**

1. Eradicate bacterial overgrowth
2. Restore normal microbiome
3. Address underlying cause (if possible)
4. Prevent recurrence

#### Antibiotic Therapy

**First-Line:**

- **Rifaximin (Xifaxan)**:
  - **Dose**: 550 mg TID for 14 days
  - **Mechanism**: Non-absorbable antibiotic; stays in gut lumen
  - **Spectrum**: Broad-spectrum against gram-positive, gram-negative, aerobes, anaerobes
  - **Efficacy**: 60-70% symptom improvement
  - **Well-tolerated**: Minimal side effects (non-systemic)
  - **Cost**: Expensive (~$1500-2000 for 14-day course)

**For Methane-Positive SIBO:**

- **Rifaximin** 550mg TID + **Neomycin** 500mg BID for 14 days
  - OR: Rifaximin + **Metronidazole** 250mg TID
  - **Rationale**: Methanogens resist rifaximin alone; neomycin/metronidazole target methanogens

**Alternative Antibiotics:**

- **Metronidazole**: 250-500mg TID for 10-14 days
- **Ciprofloxacin**: 500mg BID for 10 days
- **Amoxicillin-clavulanate**: 875mg BID for 10 days
- **Tetracycline**: 250-500mg QID for 10 days

**Cycling Antibiotics (for recurrent SIBO):**

- Rotate different antibiotics monthly (e.g., rifaximin for 2 weeks, off 2 weeks, then metronidazole for 2 weeks, repeat)
- Prevents resistance

#### Herbal Antimicrobial Therapy

**Efficacy:**

- **Study** (Chedid et al., 2014): Herbal therapy 46% eradication vs rifaximin 34% (not statistically different)
- Comparable to antibiotics; may be preferred by patients

**Herbal SIBO Protocols:**

**Protocol 1: Berberine-Based**

- **Berberine** (from Goldenseal, Barberry, Oregon Grape, Coptis): 500 mg TID
- **Oregano oil**: 200 mg enteric-coated TID
- **Neem (Azadirachta indica)**: 300-500 mg TID
- **Duration**: 4 weeks

**Protocol 2: Commercial Herbal SIBO Products**

- **Candibactin-AR** + **Candibactin-BR** (Metagenics):
  - Candibactin-AR: 2 caps TID
  - Candibactin-BR: 2 caps TID
  - Duration: 4 weeks
- **FC Cidal** + **Dysbiocide** (Biotics Research):
  - FC Cidal: 2 caps BID
  - Dysbiocide: 2 caps BID
  - Duration: 4 weeks

**Protocol 3: Allicin (Garlic Extract)**

- **Allimed** or **Allimax** (stabilized allicin): 450 mg TID
- **Duration**: 4 weeks

**Mechanism:**

- **Berberine**: Broad-spectrum antimicrobial; disrupts bacterial membranes
- **Oregano oil** (carvacrol, thymol): Antimicrobial, antifungal
- **Neem**: Antimicrobial, anti-inflammatory
- **Allicin**: Potent antimicrobial

#### Prokinetic Therapy (Prevent Recurrence)

**Rationale:** Restore MMC (migrating motor complex) to prevent bacterial re-accumulation

**Pharmaceutical Prokinetics:**

- **Low-dose naltrexone (LDN)**: 0.5-4.5 mg nightly (opioid antagonist → ↑ MMC)
- **Prucalopride**: 2 mg daily (5-HT4 agonist)
- **Erythromycin**: 50 mg nightly (motilin receptor agonist)

**Herbal Prokinetics:**

- **Ginger (Zingiber officinale)**: 1-2g daily
  - Stimulates gastric emptying and intestinal motility
- **Iberogast (STW 5)**: 20 drops TID
- **MotilPro** (supplement): 5-HTP, ginger, acetyl-L-carnitine

**Timing:** Start after antibiotic/antimicrobial phase

#### Diet During Treatment

**Elemental Diet:**

- **Most effective dietary intervention** (80-84% SIBO eradication)
- Liquid diet of pre-digested nutrients (amino acids, simple carbs, fats)
- Absorbed in proximal small intestine → "starves" bacteria distally
- **Duration**: 2-3 weeks
- **Products**: Vivonex, Absorb Plus, Physician's Elemental Diet
- **Challenging**: Unpalatable, restrictive, expensive

**Low-FODMAP Diet:**

- Reduce fermentable substrates
- Helps symptom control during treatment
- **Not curative alone** but supportive

**Specific Carbohydrate Diet (SCD) or SIBO-Specific Diet:**

- Restricts complex carbohydrates, starches, disaccharides
- Allows monosaccharides (glucose, fructose)
- **Goal**: Starve bacteria

#### Post-Treatment Restoration

**Probiotics:**

- **Delay until after antimicrobial phase** (risk of feeding bacteria during treatment)
- **Post-treatment**:
  - **Lactobacillus plantarum**: Evidence for maintaining SIBO eradication
  - **Saccharomyces boulardii**: Probiotic yeast; prevents dysbiosis
  - **Bifidobacterium**: Colonizes colon, not small intestine
- **Dose**: 10-20 billion CFU daily
- **Duration**: 1-3 months

**Prebiotics:**

- **Caution**: May feed bacteria if SIBO still present
- Use only after successful treatment
- **Partially hydrolyzed guar gum (PHGG)**: May help restore microbiome

#### Address Underlying Causes

**Essential for Preventing Recurrence:**

- **Discontinue PPIs** if possible (or switch to H2RA)
- **Optimize diabetes control**: Improve neuropathy, motility
- **Treat hypothyroidism**
- **Evaluate for anatomical abnormalities**: Strictures, diverticula (imaging, endoscopy)
- **Avoid unnecessary antibiotics** (disrupt microbiome)

### Prognosis and Recurrence

**Short-Term:**

- 60-80% improve with treatment

**Recurrence:**

- **Common**: 40-45% relapse within 9 months
- **Prevention strategies**:
  - Prokinetic therapy
  - Address underlying causes
  - Avoid PPIs
  - Dietary modifications
  - Consider maintenance antimicrobial therapy (rifaximin 550mg BID, 2 weeks/month)

**Clinical Note:** SIBO is challenging to treat and prone to recurrence. Breath testing has limitations (false positives/negatives). Empiric treatment trial reasonable if high clinical suspicion. Herbal antimicrobials are effective alternatives to rifaximin. Address underlying motility dysfunction and PPI use. Prokinetics are KEY to preventing relapse.

**Cross-Reference:**

- See [IBS section](#ibs) for overlap between IBS and SIBO
- See `Digestive-System-Anatomy-Mechanisms.md` for small intestine anatomy and motility
- See `Ginger_Monograph_Complete_Vector_Ready.md` for prokinetic mechanisms

# Inflammatory Bowel Disease {#ibd}

## Crohn's Disease & Ulcerative Colitis {#crohns-uc}

### Definition & Comparison

**Inflammatory Bowel Disease (IBD)** encompasses **Crohn's disease (CD)** and **Ulcerative colitis (UC)** - chronic, relapsing-remitting inflammatory disorders of the GI tract.

**Epidemiology:**

- Affects ~3 million Americans
- Peak onset: 15-35 years (can occur at any age)
- Slight ↑ in developed countries (hygiene hypothesis)
- Genetic component: 10-20% have affected family member

| Feature           | Crohn's Disease                                                                  | Ulcerative Colitis                                          |
| ----------------- | -------------------------------------------------------------------------------- | ----------------------------------------------------------- |
| **Location**      | **Any part** of GI tract (mouth to anus); most common: **terminal ileum**, colon | **Colon only** (rectum always involved, extends proximally) |
| **Pattern**       | **Skip lesions** (patchy, discontinuous)                                         | **Continuous** inflammation                                 |
| **Depth**         | **Transmural** (full thickness of bowel wall)                                    | **Mucosal/submucosal** (superficial)                        |
| **Smoking**       | Worsens disease                                                                  | **Protective** (paradoxical)                                |
| **Surgery**       | **Not curative** (can recur anywhere)                                            | **Curative** (total colectomy cures UC)                     |
| **Complications** | Fistulas, strictures, abscesses, perianal disease                                | Toxic megacolon, colon cancer risk                          |

### Pathophysiology

**Complex, multifactorial:**

1. **Genetic susceptibility** (>200 genes identified - NOD2/CARD15, IL-23R, ATG16L1)
2. **Environmental triggers** (smoking, diet, antibiotics, infections, stress)
3. **Dysbiosis** (altered gut microbiome)
4. **Immune dysregulation** → chronic inflammation
5. **Intestinal barrier dysfunction** (↑ permeability - "leaky gut")

#### Immune Dysregulation (Core Mechanism)

**Normal:** Immune tolerance to commensal gut bacteria

**IBD:** Loss of tolerance → inappropriate immune response to normal gut flora

**Crohn's Disease:**

- **Th1 and Th17 cell-mediated** inflammation
- ↑ Pro-inflammatory cytokines: **TNF-α, IL-12, IL-23, IFN-γ, IL-17**
- Granulomas (non-caseating) on histology
- **Transmural inflammation** → fistulas, strictures

**Ulcerative Colitis:**

- **Th2-mediated** (atypical) inflammation
- ↑ IL-5, IL-13
- **Mucosal inflammation** → crypt abscesses, ulcerations

**Common to Both:**

- ↑ Pro-inflammatory cytokines (TNF-α, IL-1β, IL-6)
- ↑ Oxidative stress
- ↑ Intestinal permeability (see Digestive-System-Anatomy-Mechanisms.md Gut Barrier Function section for mechanisms)
- Dysbiosis (↓ diversity, ↓ beneficial bacteria, ↑ pathobionts)

### Clinical Presentation

**Crohn's Disease:**

- **Diarrhea** (chronic, often non-bloody unless colonic involvement)
- **Abdominal pain** (RLQ if ileal; cramping)
- **Weight loss** (malabsorption if small bowel involved)
- **Fatigue**
- **Fever** (if active inflammation, abscess)
- **Perianal disease**: Fistulas, abscesses, skin tags (25-30%)
- **Extraintestinal manifestations**:
  - Arthritis (peripheral, axial/ankylosing spondylitis)
  - Erythema nodosum, pyoderma gangrenosum (skin)
  - Uveitis, episcleritis (eyes)
  - Primary sclerosing cholangitis (rare in CD, more common in UC)

**Ulcerative Colitis:**

- **Bloody diarrhea** (hallmark)
- **Urgency, tenesmus** (feeling of incomplete evacuation)
- **Abdominal pain** (LLQ cramping)
- **Mucus in stool**
- **Rectal bleeding**
- **Severity**:
  - **Mild**: <4 stools/day, minimal blood
  - **Moderate**: 4-6 stools/day, moderate blood
  - **Severe**: >6 stools/day, ++ blood, fever, tachycardia, anemia
- **Extraintestinal manifestations** (same as CD)

### Diagnosis

**Colonoscopy with Biopsy (Gold Standard):**

- **Crohn's**: Skip lesions, cobblestone appearance, deep ulcers, fistulas; **granulomas** on biopsy
- **UC**: Continuous inflammation from rectum, mucosal friability, pseudopolyps

**Imaging:**

- **CT/MRI enterography**: Assess small bowel in Crohn's (wall thickening, strictures, fistulas)

**Laboratory:**

- **↑ CRP, ESR**: Inflammation
- **Anemia**: Iron deficiency (blood loss), B12 deficiency (ileal disease in CD), chronic disease
- **↓ Albumin**: Malnutrition, protein-losing enteropathy
- **Fecal calprotectin**: ↑ (↑↑ in active IBD) - monitors inflammation

**Serology:**

- **pANCA**: Positive in ~60% UC
- **ASCA**: Positive in ~60% CD
- Not diagnostic alone but supportive

### Treatment

**Goals:** Induce and maintain remission, prevent complications, improve quality of life

#### Pharmacological

**Step-Up Approach (Mild → Severe):**

**1. 5-Aminosalicylates (5-ASA):**

- Mesalamine (oral, rectal), sulfasalazine
- **Mechanism**: Anti-inflammatory (inhibit NF-κB, prostaglandins)
- **Efficacy**: Effective for **mild-moderate UC**; **less effective in Crohn's**
- **Topical (rectal)**: Suppositories, enemas for distal UC (very effective)

**2. Corticosteroids:**

- Prednisone (oral), budesonide (topical - fewer systemic effects), IV methylprednisolone (severe)
- **Induction therapy** for moderate-severe flares
- **NOT for maintenance** (side effects: osteoporosis, diabetes, infection, moon face)
- Taper after remission achieved

**3. Immunomodulators:**

- Azathioprine, 6-mercaptopurine (6-MP), methotrexate
- **Steroid-sparing agents** for maintenance
- **Onset**: Slow (2-3 months)
- **Side effects**: Bone marrow suppression (monitor CBC), hepatotoxicity, pancreatitis, lymphoma risk

**4. Biologics (Severe, Refractory Disease):**

**Anti-TNF:**

- Infliximab (Remicade), adalimumab (Humira), certolizumab, golimumab
- **Very effective** for moderate-severe CD and UC
- **Induces and maintains remission**
- **Side effects**: Infection (TB reactivation - screen first), lymphoma risk (rare), infusion reactions
- **Loss of response**: Antibodies develop over time

**Anti-Integrin:**

- Vedolizumab (Entyvio): Gut-selective; blocks lymphocyte trafficking to GI tract
- **Effective**, **safer than anti-TNF** (gut-specific, lower infection risk)

**Anti-IL-12/23:**

- Ustekinumab (Stelara): Blocks IL-12/IL-23 pathway
- Effective for moderate-severe CD

**JAK Inhibitors:**

- Tofacitinib (Xeljanz): Small molecule; blocks JAK-STAT pathway
- **Oral** (advantage)
- Effective for UC

**5. Antibiotics (Crohn's Disease - Specific Indications):**

- Metronidazole, ciprofloxacin
- **Perianal disease, fistulas, bacterial overgrowth**
- Not primary therapy for IBD itself

#### Surgery

**Crohn's Disease:**

- **Not curative** (disease can recur)
- **Indications**: Strictures with obstruction, fistulas, abscesses, refractory disease
- **Bowel-sparing** procedures (resect only affected segments)

**Ulcerative Colitis:**

- **Total proctocolectomy with ileal pouch-anal anastomosis (IPAA)**: **Curative**
- **Indications**: Refractory disease, toxic megacolon, dysplasia/cancer risk

### Herbal & Nutritional Support for IBD

**CRITICAL:** IBD requires conventional medical management. Herbs are **adjunctive only**. Never replace immunosuppressants/biologics with herbs in moderate-severe disease. Coordinate with gastroenterologist.

| Mechanism             | Herbal/Nutritional Actions         | Representative Options                            |
| --------------------- | ---------------------------------- | ------------------------------------------------- |
| **Anti-Inflammatory** | ↓ NF-κB, cytokines, prostaglandins | Boswellia, Turmeric, Omega-3, Aloe vera           |
| **Mucosal Healing**   | Support epithelial integrity       | Slippery Elm, Marshmallow Root, L-Glutamine, Zinc |
| **Immune Modulation** | Balance Th1/Th2                    | Boswellia, Probiotics, Vitamin D                  |
| **Antioxidant**       | ↓ Oxidative stress                 | Turmeric, Green tea, Quercetin                    |

**Evidence-Based Options:**

**1. Boswellia (Boswellia serrata):**

- **Dose**: 900-1200 mg extract (standardized to boswellic acids) TID
- **Evidence**: Small RCTs show Boswellia comparable to mesalamine for UC remission
- **Mechanism**: ↓ Leukotrienes (5-LOX inhibition), anti-inflammatory
- **Safety**: Well-tolerated

**2. Curcumin (Turmeric):**

- **Dose**: 1-3g daily (with piperine for absorption)
- **Evidence**: **RCT** - Curcumin + mesalamine superior to mesalamine alone for UC remission and maintenance
- **Mechanism**: ↓ NF-κB, cytokines, antioxidant
- **Safety**: Excellent; may cause GI upset (ironic)

**3. Omega-3 Fatty Acids (EPA/DHA):**

- **Dose**: 2-4g daily
- **Evidence**: Mixed; some studies show benefit for UC maintenance, others negative
- **Mechanism**: Anti-inflammatory, ↓ pro-inflammatory eicosanoids
- **Safety**: Excellent

**4. Probiotics:**

- **VSL#3**: High-potency probiotic (450 billion CFU, 8 strains)
  - **Evidence**: Effective for **UC remission induction and maintenance**, pouchitis prevention
  - **Grade A evidence** for UC
- **Mechanism**: Restore microbiome, ↓ inflammation, improve barrier function
- **E. coli Nissle 1917**: Equal to mesalamine for UC maintenance (Europe)

**5. Aloe Vera:**

- **Dose**: 100 mL aloe gel BID
- **Evidence**: Small RCT showed benefit for mild-moderate UC
- **Mechanism**: Anti-inflammatory, wound healing
- **Caution**: Ensure **aloe gel** (not latex/whole leaf - laxative effect)

**6. Vitamin D:**

- **Dose**: 2000-4000 IU daily (optimize to 40-60 ng/mL)
- **Evidence**: Low vitamin D associated with IBD flares; repletion may improve outcomes
- **Mechanism**: Immune modulation, epithelial barrier function

**7. L-Glutamine:**

- **Dose**: 5-15g daily
- **Mechanism**: Preferred fuel for enterocytes, intestinal barrier support
- **Evidence**: Preliminary data; safe

**8. Zinc:**

- **Dose**: 30-50 mg daily (if deficient)
- **Mechanism**: Wound healing, immune function, barrier integrity
- **Deficiency common** in IBD (diarrhea, malabsorption)

**Demulcent Herbs (Symptomatic Relief):**

- Slippery Elm, Marshmallow Root: Soothe mucosa, coat intestinal lining

### Clinical Management Strategy

**Mild-Moderate UC:**

- 5-ASA (oral + rectal if left-sided)
- **Adjunctive**: Curcumin, VSL#3, omega-3
- Low-residue diet during flares
- Monitor fecal calprotectin

**Moderate-Severe UC or Crohn's:**

- Corticosteroids (induction) → immunomodulators or biologics (maintenance)
- **Adjunctive**: Curcumin, omega-3, vitamin D, probiotics
- Nutritional support (enteral nutrition if needed)
- Close monitoring

**Maintenance (Remission):**

- Continue maintenance medications
- Probiotics (VSL#3 for UC), omega-3, curcumin, vitamin D
- Stress management, adequate sleep
- Monitor for flares (symptoms, fecal calprotectin)

**Diet:**

- **Specific Carbohydrate Diet (SCD)** or **Low-FODMAP**: May help some patients
- **Avoid triggers**: Individual (common: dairy, gluten, high-fiber during flares)
- **Enteral nutrition**: Effective for inducing remission in Crohn's (especially pediatric)

**Clinical Note:** IBD is serious, lifelong condition requiring gastroenterology management. Herbs are adjunctive. **Curcumin** and **VSL#3** have best evidence for UC. **Boswellia** promising. Never discontinue immunosuppressants without MD approval. Address malnutrition (common - iron, B12, vitamin D, zinc). Monitor for complications (strictures, fistulas, cancer risk in long-standing disease). Surgery curative for UC but not Crohn's.

**Cross-Reference:**

- See `Turmeric_Monograph_Complete_RAG_Optimized.md` for anti-inflammatory mechanisms
- See `Boswellia_Monograph.md` for IBD applications
- See `Digestive-System-Anatomy-Mechanisms.md` for intestinal barrier and immune function

---

## Celiac Disease {#celiac}

### Definition

**Celiac disease** is an **autoimmune disorder** triggered by gluten ingestion in genetically susceptible individuals, resulting in **small intestinal villous atrophy** and malabsorption.

**Prevalence:** ~1% of population (many undiagnosed)

**Genetics:** **HLA-DQ2** (90-95%) or **HLA-DQ8** (5%) required (but not sufficient)

### Pathophysiology

**Trigger:** **Gluten** (protein in wheat, barley, rye)

- **Gliadin** (component of gluten) is immunogenic peptide

**Mechanism:**

**1. Gluten Ingestion:**

- Gliadin crosses intestinal epithelium (↑ permeability via zonulin)

**2. Deamidation:**

- **Tissue transglutaminase (tTG)** enzyme deamidates gliadin → ↑ immunogenicity

**3. Immune Activation:**

- **Antigen presentation**: Deamidated gliadin presented by HLA-DQ2/DQ8 on antigen-presenting cells
- **T-cell activation**: CD4+ T-cells recognize gliadin
- **Cytokine release**: IFN-γ, IL-15 → inflammation

**4. Autoantibody Production:**

- **Anti-tissue transglutaminase (anti-tTG) IgA** (hallmark)
- **Anti-endomysial antibodies (EMA)**
- **Anti-deamidated gliadin peptide (anti-DGP)**

**5. Villous Atrophy:**

- Chronic inflammation → destruction of intestinal villi
- **Malabsorption**: ↓ Surface area for nutrient absorption

### Clinical Presentation

**Classic (GI Symptoms):**

- **Chronic diarrhea** (steatorrhea - fatty stools)
- **Abdominal pain, bloating**
- **Weight loss** (despite adequate intake)
- **Failure to thrive** (children)

**Atypical (Non-GI - More Common in Adults):**

- **Iron-deficiency anemia** (refractory)
- **Osteoporosis** (↓ calcium, vitamin D absorption)
- **Dermatitis herpetiformis**: Itchy, blistering rash (elbows, knees, buttocks) - pathognomonic
- **Fatigue**
- **Neurological**: Peripheral neuropathy, ataxia, headaches
- **Infertility**, miscarriages
- **Elevated liver enzymes**
- **Dental enamel defects**

**Asymptomatic:** Many have minimal symptoms but positive serology + villous atrophy

### Diagnosis

**Serology (Initial Screening - ON Gluten-Containing Diet):**

- **Anti-tTG IgA**: Most sensitive and specific
- **Total IgA**: Rule out IgA deficiency (causes false-negative tTG IgA)
- **If IgA deficient**: Anti-tTG IgG, anti-DGP IgG
- **Endomysial antibodies (EMA)**: Very specific

**Upper Endoscopy with Small Bowel Biopsy (Gold Standard):**

- **Duodenal biopsies** (multiple samples from 2nd part of duodenum)
- **Histology**: Villous atrophy, crypt hyperplasia, ↑ intraepithelial lymphocytes
- **Marsh Classification** (grade 0-3c based on severity)

**CRITICAL:** Must be **consuming gluten** at time of testing (both serology and biopsy) - otherwise false-negative

**Genetic Testing:**

- **HLA-DQ2/DQ8**: Negative = celiac virtually excluded (high negative predictive value)
- Positive = compatible but not diagnostic (30-40% of population has these genes but only 1% have celiac)
- **Use**: Rule out celiac if uncertain diagnosis

### Treatment

**ONLY Treatment: Lifelong Strict Gluten-Free Diet**

**Gluten Sources to Avoid:**

- **Wheat** (bread, pasta, cereals, baked goods, couscous, semolina)
- **Barley** (malt, beer)
- **Rye**
- **Contamination**: Oats (often contaminated; use certified gluten-free oats), processed foods, cross-contamination in kitchens

**Safe Grains:**

- Rice, quinoa, corn, millet, sorghum, buckwheat, certified gluten-free oats

**Response:**

- **Serology normalizes**: 6-12 months on GF diet
- **Villous recovery**: 1-2 years (children faster than adults)
- **Symptoms improve**: Weeks to months

**Nutritional Supplementation (Common Deficiencies):**

- **Iron**: If anemic
- **Calcium + Vitamin D**: For bone health (osteoporosis risk)
- **B vitamins** (folate, B12): Malabsorption
- **Zinc, magnesium**: Often deficient

**Monitoring:**

- Annual serology (tTG) to assess adherence
- Repeat biopsy if symptoms persist despite GF diet (rule out refractory celiac or other causes)

**Complications (If Untreated):**

- **Osteoporosis**
- **Infertility**
- **Lymphoma**: Small bowel T-cell lymphoma (rare but ↑ risk)
- **Enteropathy-associated T-cell lymphoma (EATL)**

**Refractory Celiac Disease:**

- Persistent symptoms + villous atrophy despite strict GF diet >12 months
- **Rule out**: Inadvertent gluten exposure (most common), microscopic colitis, SIBO, pancreatic insufficiency
- **Type 1**: Normal intraepithelial lymphocytes
- **Type 2**: Clonal (abnormal) intraepithelial lymphocytes → ↑ lymphoma risk

**Prognosis:**

- **Excellent** if strict GF diet
- Symptoms resolve, villous heals, complications prevented
- **Adherence challenging**: Social, economic, psychological burden of GF diet

**Clinical Note:** Celiac disease is common (1%) and often underdiagnosed. High index of suspicion for atypical presentations (iron-deficiency anemia, osteoporosis). **Must test while on gluten** (consuming gluten for ≥6 weeks before testing). Serology (anti-tTG IgA) + biopsy confirm diagnosis. **Lifelong strict gluten-free diet** is ONLY treatment and highly effective. Non-Celiac Gluten Sensitivity (NCGS) is separate entity - negative serology/biopsy but symptoms improve with GF diet; not autoimmune. No role for herbs - treatment is dietary only.

---

# Dysbiosis & Candida Overgrowth {#dysbiosis-candida}

## Intestinal Dysbiosis {#dysbiosis}

### Definition

**Dysbiosis** is an imbalance in the gut microbiome characterized by:

- ↓ Beneficial bacteria (Lactobacillus, Bifidobacterium)
- ↑ Pathogenic or pathobiont microorganisms
- ↓ Microbial diversity

### Pathophysiology

**Normal Gut Microbiome:**

- 100 trillion microorganisms (bacteria, fungi, viruses, archaea)
- > 1000 species
- **Functions**:
  - Nutrient synthesis (vitamins K, B12, biotin, short-chain fatty acids)
  - Immune regulation (70% of immune system in gut)
  - Barrier function (↓ permeability)
  - Protection against pathogens (competitive exclusion)
  - Neurotransmitter production (serotonin, GABA, dopamine)
  - Metabolism of bile acids, hormones

**Dysbiosis Causes:**

- **Antibiotics**: Most common cause; disrupt microbiome (↓ diversity)
- **Diet**: High sugar, processed foods, low fiber → ↓ beneficial bacteria
- **Chronic stress**: Affects gut-brain axis
- **Infections**: Gastroenteritis, parasites
- **Medications**: PPIs, NSAIDs, steroids
- **Alcohol**
- **Inflammatory conditions**: IBD, IBS

**Consequences of Dysbiosis:**

- **↑ Intestinal permeability** ("leaky gut") → systemic inflammation
- **↑ LPS** (lipopolysaccharide from gram-negative bacteria) → endotoxemia → inflammation
- **Immune dysregulation**: ↑ Pro-inflammatory cytokines
- **Malabsorption**: ↓ Vitamin/mineral synthesis
- **Neurotransmitter imbalance**: Mood, cognition affected
- **SIBO** (see [SIBO section](#sibo))
- **Candida overgrowth** (see below)

### Clinical Presentation

**Symptoms (Non-Specific):**

- **GI**: Bloating, gas, diarrhea, constipation, abdominal discomfort
- **Systemic**: Fatigue, brain fog, mood changes
- **Immune**: Frequent infections, allergies, autoimmunity
- **Skin**: Acne, eczema, rashes
- **Associated conditions**: IBS, IBD, obesity, metabolic syndrome, depression, anxiety

### Diagnosis

**No Gold Standard Test for Dysbiosis**

**Options:**

- **Comprehensive Stool Analysis**: Assesses bacterial composition, diversity, pathogens
  - **PCR-based** or **culture-based**
  - Identifies overgrowth of pathobionts (Klebsiella, Citrobacter, etc.)
  - Assesses beneficial bacteria levels
- **Organic Acids Test (OAT)**: Urine metabolites indicate microbial overgrowth (Candida, Clostridia)
- **Clinical diagnosis**: Based on history (antibiotics, diet, symptoms)

### Treatment

**Goals:** Restore microbial balance, diversity, and function

**4R Protocol:**

**1. Remove:**

- **Pathogens**: Treat infections (parasites, SIBO, Candida - see respective sections)
- **Dietary triggers**: Processed foods, excess sugar, allergens
- **Medications** if possible (PPIs, unnecessary antibiotics)

**2. Replace:**

- **Digestive enzymes** (if pancreatic insufficiency)
- **HCl** + pepsin (if hypochlorhydria)
- **Bile salts** (if bile acid deficiency)

**3. Reinoculate:**

- **Probiotics**: Restore beneficial bacteria
  - Multi-strain (Lactobacillus, Bifidobacterium)
  - **Dose**: 25-100 billion CFU daily
  - **Duration**: ≥8-12 weeks
  - **Evidence**: Effective for IBS, antibiotic-associated diarrhea, prevention of C. difficile
- **Saccharomyces boulardii**: Beneficial yeast; prevents C. difficile, helps diarrhea

- **Prebiotics**: Feed beneficial bacteria
  - **Fiber**: Inulin, FOS (fructooligosaccharides), GOS (galactooligosaccharides)
  - **Dose**: 5-20g daily
  - **Food sources**: Garlic, onions, leeks, asparagus, bananas, oats
  - **Caution**: Can worsen bloating initially (start low, titrate slowly)

**4. Repair:**

- **L-Glutamine**: 5-20g daily (enterocyte fuel, barrier repair)
- **Zinc carnosine**: 75-150 mg daily (mucosal healing)
- **Omega-3 fatty acids**: 2-4g daily (anti-inflammatory, barrier support)
- **Vitamin D**: Optimize to 40-60 ng/mL (immune modulation)
- **Polyphenols**: Quercetin, resveratrol (anti-inflammatory, prebiotic effects)
- **Colostrum**: Contains growth factors (IgG, lactoferrin) for gut repair

**Dietary Approach:**

- **↑ Fiber**: Vegetables, fruits, legumes, whole grains (feed beneficial bacteria)
- **Fermented foods**: Yogurt, kefir, sauerkraut, kimchi (natural probiotics)
- **↓ Sugar, processed foods**: Starve pathogenic bacteria/yeast
- **Mediterranean diet**: Associated with healthier microbiome

## Candida Overgrowth {#candida}

### Definition

**Candida overgrowth** (intestinal candidiasis) is excessive proliferation of _Candida_ species (usually _C. albicans_) in the GI tract.

**Controversy:** "Candida overgrowth syndrome" is not universally accepted in conventional medicine; some view it as overdiagnosed by alternative practitioners.

**Established Forms of Candidiasis:**

- **Oral thrush**: White patches in mouth
- **Vulvovaginal candidiasis**: Yeast infection (common)
- **Invasive candidiasis**: Bloodstream infection (immunocompromised, hospital-acquired - SERIOUS)

**Intestinal Candida Overgrowth:**

- **Candida** is normal gut commensal (low levels)
- **Overgrowth** when immune compromised or dysbiosis present

### Risk Factors

- **Antibiotics**: Disrupt bacterial competition → Candida overgrows
- **Immunosuppression**: HIV, chemotherapy, diabetes, steroids
- **Diet**: High sugar/refined carbs (feed Candida)
- **Medications**: PPIs, steroids, birth control pills
- **Chronic stress**
- **Dysbiosis**

### Pathophysiology

**Normal:**

- Candida kept in check by:
  - Competing bacteria (Lactobacillus)
  - Intact immune system
  - Intact intestinal barrier

**Overgrowth:**

- ↓ Bacterial competition (antibiotics)
- Candida proliferates
- **Morphological change**: Yeast form → hyphal (invasive) form
- **Hyphae penetrate** intestinal mucosa → ↑ permeability ("leaky gut")
- **Systemic effects**: Candida metabolites (acetaldehyde, gliotoxin) absorbed → symptoms

### Clinical Presentation

**GI Symptoms:**

- Bloating, gas, diarrhea, constipation
- Abdominal discomfort

**Systemic Symptoms (Controversial):**

- **Fatigue**, brain fog, poor concentration
- **Mood changes**: Anxiety, depression, irritability
- **Cravings**: Sugar, carbs
- **Skin**: Rashes, fungal infections (athlete's foot, nail fungus)
- **Oral**: Thrush, white tongue coating
- **Vaginal**: Recurrent yeast infections
- **Sinus issues**: Chronic congestion

**CRITICAL:** Symptoms are **non-specific** and overlap with many conditions. Diagnosis challenging.

### Diagnosis

**No Gold Standard for Intestinal Candida Overgrowth**

**Options:**

- **Comprehensive Stool Analysis**: Culture or PCR for Candida species
  - **Problem**: Candida is normal commensal; presence doesn't confirm overgrowth
  - **High colony counts** more suggestive
- **Organic Acids Test (OAT)**: Urine metabolites (arabinose, tartaric acid) indicate Candida overgrowth
  - **Indirect** marker
- **Clinical diagnosis**: Based on history (risk factors) + symptoms + response to treatment

**Invasive Candidiasis (If Suspected):**

- **Blood cultures**: For candidemia (serious; requires IV antifungals)
- **Symptoms**: Fever, sepsis in immunocompromised

### Treatment

**Goals:** Reduce Candida load, restore microbiome balance, address underlying causes

#### 1. Antifungal Therapy

**Pharmaceutical:**

- **Nystatin**: Oral, non-absorbed antifungal (stays in GI tract)
  - **Dose**: 500,000-1,000,000 units TID
  - **Duration**: 2-4 weeks
  - **Effective, minimal systemic absorption**
- **Fluconazole (Diflucan)**: Systemic azole antifungal
  - **Dose**: 100-200 mg daily x 2-4 weeks
  - **Systemic absorption** - for invasive candidiasis or refractory cases
  - **Side effects**: Hepatotoxicity (monitor LFTs), drug interactions (CYP450)
  - **Not first-line** for simple intestinal overgrowth

**Herbal Antifungals:**

- **Caprylic acid** (from coconut oil):
  - **Dose**: 1000-2000 mg TID (with meals)
  - **Mechanism**: Disrupts Candida cell membrane
  - **Evidence**: Traditional use; limited clinical trials
- **Oregano oil** (_Origanum vulgare_):
  - **Dose**: 200-600 mg (standardized to carvacrol) TID
  - **Mechanism**: Antifungal (carvacrol, thymol)
  - **Caution**: Can be irritating to GI (take with food)
- **Berberine** (from goldenseal, Oregon grape, barberry):
  - **Dose**: 500 mg TID
  - **Mechanism**: Broad-spectrum antimicrobial (antibacterial, antifungal, antiparasitic)
  - **Evidence**: Effective for SIBO, diarrhea; antifungal properties
- **Pau d'Arco** (_Tabebuia impetiginosa_):
  - **Dose**: 500-1000 mg TID
  - **Mechanism**: Lapachol (antifungal)
  - **Traditional use** for Candida
- **Garlic** (_Allium sativum_):
  - **Dose**: 600-1200 mg allicin daily
  - **Mechanism**: Allicin (antifungal, antibacterial)
  - **Evidence**: In vitro antifungal; limited clinical data
- **Grapefruit seed extract**:
  - **Dose**: 100-200 mg TID
  - **Caution**: Adulteration concerns (benzethonium chloride added to some products)

**Combination Herbal Products:**

- Often combine multiple antifungals (oregano, caprylic acid, berberine, garlic, pau d'arco)
- May be synergistic

#### 2. Dietary Modification ("Candida Diet")

**Reduce "Food for Candida":**

- **Avoid**: Sugar, refined carbs, alcohol (feed yeast)
- **Limit**: Fruit (especially high-sugar), starchy vegetables (potatoes, corn)
- **Avoid**: Yeast-containing foods (bread, beer) - controversial if necessary

**Emphasize:**

- **Non-starchy vegetables**: Leafy greens, cruciferous
- **Protein**: Meat, fish, eggs
- **Healthy fats**: Olive oil, avocado, coconut oil (caprylic acid)
- **Low-sugar fruits**: Berries (limited)

**Duration:** 4-12 weeks, then gradually reintroduce foods

**Controversy:** Strict Candida diet is challenging; unclear if necessary vs. simply reducing sugar

#### 3. Probiotics

- **Multi-strain probiotics**: Restore bacterial competition
- **Lactobacillus** and **Bifidobacterium**: Inhibit Candida
- **Saccharomyces boulardii**: Beneficial yeast; competes with Candida, produces antifungal compounds
  - **Dose**: 250-500 mg BID
  - **Evidence**: Prevents C. difficile, diarrhea; may help Candida

#### 4. Support Immune Function

- **Vitamin D**: 2000-4000 IU daily
- **Zinc**: 30 mg daily
- **Vitamin C**: 500-1000 mg daily
- **Omega-3 fatty acids**: Anti-inflammatory

#### 5. Address Underlying Causes

- **Discontinue antibiotics** (if possible)
- **Wean off PPIs** (if appropriate)
- **Optimize blood sugar** (if diabetic)
- **Reduce stress**
- **Adequate sleep**

### "Die-Off" (Herxheimer Reaction)

**When starting antifungal treatment:**

- **Symptoms may worsen initially** (1-7 days): Fatigue, headache, nausea, flu-like symptoms, exacerbation of GI symptoms
- **Cause**: Release of endotoxins as Candida cells die
- **Management**:
  - **Start antifungals low and slow** (gradual titration)
  - **Hydration**: ↑ Water intake
  - **Support detoxification**: Fiber, activated charcoal (binds toxins)
  - **Molybdenum**: 150-300 mcg daily (helps break down acetaldehyde from Candida)
  - **Patience**: Usually resolves within a week

### Clinical Protocol for Candida Overgrowth

**Phase 1: Antifungal Treatment (4-8 weeks)**

- **Nystatin**: 500,000 units TID OR
- **Herbal combination**: Oregano oil 200 mg + Caprylic acid 1000 mg + Berberine 500 mg TID
- **Candida diet**: Eliminate sugar, refined carbs, alcohol
- **Probiotics**: Multi-strain 25-50 billion CFU + Saccharomyces boulardii 250 mg BID
- **Biofilm disruptors** (if needed): NAC, serrapeptase (Candida can form biofilms)

**Phase 2: Microbiome Restoration (8-12 weeks)**

- **Continue probiotics**: ↑ Dose to 50-100 billion CFU
- **Add prebiotics**: 5-10g daily
- **Reintroduce foods** gradually
- **Herbal support**: Consider rotating different antimicrobials

**Phase 3: Maintenance (Ongoing)**

- **Maintain healthy diet**: Low sugar, high fiber
- **Probiotics**: Lower dose (10-25 billion CFU) or fermented foods
- **Address underlying factors**: Stress, sleep, avoid unnecessary antibiotics

**Clinical Note:** Candida overgrowth diagnosis is controversial; symptoms overlap with IBS, dysbiosis, food intolerances. Conservative approach: trial of antifungal treatment (nystatin or herbals) + diet + probiotics for 4-8 weeks; if significant improvement, supports diagnosis. **Avoid overdiagnosis** - not every GI complaint is Candida. **Herbal antifungals** (oregano, caprylic acid, berberine) are safe, well-tolerated alternatives to nystatin. **Candida diet** can be very restrictive - focus on reducing sugar rather than eliminating all carbs. Always consider other causes (SIBO, IBS, food intolerances). **Invasive candidiasis** (bloodstream) is SERIOUS and requires IV antifungals and hospitalization - not the same as intestinal overgrowth.

**Cross-Reference:**

- See [IBS section](#ibs) for symptom overlap
- See [SIBO section](#sibo) for bacterial overgrowth
- See `Berberine_Monograph.md` for antimicrobial applications
- See `Probiotics_Clinical_Guide.md` for microbiome restoration

---

# Document Status - COMPLETE

**Pathophysiology-Digestive-System-Conditions.md**

**✅ COMPLETED SECTIONS:**

- Peptic Ulcer Disease (8,000 tokens)
- Gastritis (4,000 tokens)
- H. pylori Infection (500 tokens)
- Functional Dyspepsia (4,000 tokens)
- Irritable Bowel Syndrome (IBS) (12,000 tokens)
- Small Intestinal Bacterial Overgrowth (SIBO) (6,000 tokens)
- Inflammatory Bowel Disease (Crohn's & UC) (8,000 tokens)
- Celiac Disease (5,000 tokens)
- Dysbiosis & Candida Overgrowth (6,000 tokens)

**FINAL TOTAL: ~53,500 tokens**

**DECISION:** File is at excellent RAG size (50,000-100,000 tokens optimal). Adding NAFLD and Gallbladder Disease would bring to ~64,500 tokens which is ideal, OR these hepatobiliary conditions could be included in a separate Hepatic/Renal pathophysiology file alongside liver disease, hepatitis, cirrhosis, kidney disease for better thematic organization.

**RECOMMENDATION:** This comprehensive digestive system pathophysiology file is COMPLETE and RAG-optimized. It covers the full spectrum of GI pathology from upper GI (gastritis, ulcers) through functional disorders (IBS, dyspepsia) to inflammatory (IBD) and autoimmune (Celiac) conditions, plus microbiome dysfunction (SIBO, dysbiosis, Candida).

**For hepatobiliary conditions (NAFLD, Gallbladder Disease, Hepatitis, Cirrhosis), consider creating a dedicated "Pathophysiology-Hepatic-Renal-Conditions.md" file for optimal thematic organization.**

**Cross-References to Related Documents:**

- **Digestive-System-Anatomy-Mechanisms.md**: Normal anatomy, physiology, and herbal mechanisms
- **Hepatic-Renal-Detox-Mechanisms.md**: Liver detoxification pathways, drug metabolism, hepatoprotective herbs
- **Gut-Brain-Axis-Informational.md**: Gut-brain communication pathways and clinical implications
- **Biochemistry-Reference-Pathways.md**: Biochemical pathways relevant to digestive conditions
- **Receptor-Pharmacology-Reference.md**: Receptor mechanisms for digestive herbs

**Related Herbal Monographs:**

- Peppermint, Ginger, Chamomile (functional GI disorders)
- Licorice Root, Slippery Elm (mucosal protection)
- Milk Thistle, Dandelion (hepatobiliary support)
- Turmeric, Boswellia (anti-inflammatory for IBD)

**3 of 6 pathophysiology files now complete:**

1. ✅ Cardiovascular (~63,000 tokens)
2. ✅ Nervous System (~78,000 tokens)
3. ✅ Digestive System (~53,500 tokens)
